
Washington University

Report on Federal Financial Assistance Programs in Accordance with Uniform Guidance For the Year Ended June 30, 2023 Employer Identification Number: 43-0653611

Washington University Report on Federal Financial Assistance Programs in Accordance with Uniform Guidance Index June 30, 2023

Page(s)	A. FINANCIAL STATEMENTS AND SUPPLEMENTAL INFORMATION	A.
1–3	Report of Independent Auditors	
4-33	Consolidated Financial Statements for the Years Ended June 30, 2023 and 2022	
34–52	Schedule of Expenditures of Federal Awards	
53	Notes to Schedule of Expenditures of Federal Awards	
	B. REPORTS ON COMPLIANCE AND ON INTERNAL CONTROLS	В.
54-55	Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	
56–58	Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance	
	C. SCHEDULE OF FINDINGS AND QUESTIONED COSTS	C.
59	Part I – Summary of Auditors' Results	
60	Part II – Financial Statement Findings	
60–61	Part III – Federal Award Findings and Questioned Costs	
62	Management's Views and Corrective Action Plan	
	D. SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS	D.
63	Part IV – Summary of Status of Prior Audit Findings	





Report of Independent Auditors

To the Board of Trustees of Washington University:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of Washington University and its subsidiaries (the "University"), which comprise the consolidated statements of financial position as of June 30, 2023, and 2022, and the related consolidated statements of activities and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the University as of June 30, 2023 and 2022, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date the financial statements are issued.



Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards*, will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.



Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2023, and schedule of financial responsibility ratios as of and for the year ended June 30, 2023 are presented for purposes of additional analysis as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and the Department of Education, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards and schedule of financial responsibility ratios are fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 6, 2023 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2023. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

Pullwahmundaper LLP
St. Louis, Missouri
October 6, 2023

Washington University Consolidated Statements of Financial Position June 30, 2023 and 2022

(thousands of dollars)	2023			2022
Assets				
Cash and cash equivalents	\$	316,820	\$	239,191
Investments		14,311,571		15,416,684
Accounts and notes receivable, net		723,215		709,568
Pledges receivable, net		418,821		423,296
Right-of-use assets		93,447		76,116
Other assets		362,291		329,870
Fixed assets, net		3,566,162		3,242,141
Total assets	\$	19,792,327	\$	20,436,866
Liabilities				
Accounts payable and accrued expenses	\$	731,057	\$	643,233
Deposits, advances and other		39,428		48,139
Lease liability		104,087		87,014
Professional liability		104,012		110,170
Deferred revenue and contract liabilities		124,803		130,480
Liabilities under split-interest agreements		34,607		35,873
Government supported student loans		9,113		12,902
Notes and bonds payable		3,259,475		3,324,601
Total liabilities		4,406,582		4,392,412
Net Assets				
Without donor restrictions		7,693,793		7,847,088
With donor restrictions		7,691,952		8,197,366
Total net assets		15,385,745		16,044,454
Total liabilities and net assets	\$	19,792,327	\$	20,436,866

Washington University Consolidated Statements of Activities Year Ended June 30, 2023

(thousands of dollars)	Without Donor Restrictions	With Donor Restrictions	Total
Revenues and other support			
Tuition and fees	\$ 497,365	\$	\$ 497,365
Endowment spending distribution	552,477	17,312	569,789
Investment income	71,397	837	72,234
Gifts	110,294	93,854	204,148
Grants and contracts revenues			-
Direct costs recovered	617,177		617,177
Facilities and administrative costs recovered	235,870		235,870
Patient services, net	2,052,095		2,052,095
Auxiliary enterprises - sales and services	137,124		137,124
Educational activities - sales and services	168,263		168,263
Affiliated hospital revenues	164,808		164,808
Other revenue	38,130		38,130
Net assets released from restrictions	122,374	(122,374)	
Total revenues and other support	4,767,374	(10,371)	4,757,003
Expenses:			
Compensation expense	2,770,311		2,770,311
Supplies, services, and other	1,481,509		1,481,509
Depreciation expense	224,969		224,969
Interest expense	93,738		93,738
Total expenses	4,570,527		4,570,527
Net operating results	196,847	(10,371)	186,476
Non-operating activities:			
Investment returns net of endowment spending	(343,688)	(593,435)	(937,123)
Permanently restricted gifts	-	88,345	88,345
Other non-operating	(6,454)	10,047	3,593
Non-operating, net	(350,142)	(495,043)	(845,185)
Change in net assets	(153,295)	(505,414)	(658,709)
Net Assets, Beginning of the Year	7,847,088	8,197,366	16,044,454
Net Assets, End of the Year	\$ 7,693,793	\$ 7,691,952	\$ 15,385,745

Washington University Consolidated Statements of Activities Year Ended June 30, 2022

(thousands of dollars)	Without Donor Restrictions	With Donor Restrictions	Total
Revenues and other support			
Tuition and fees	\$ 513,132	\$	\$ 513,132
Endowment spending distribution	494,816	14,549	509,365
Investment income	10,145	385	10,530
Gifts	119,531	85,742	205,273
Grants and contracts revenues			
Direct costs recovered	579,308		579,308
Facilities and administrative costs recovered	222,969		222,969
Patient services, net	1,913,498		1,913,498
Auxiliary enterprises - sales and services	149,258		149,258
Educational activities - sales and services	187,342		187,342
Affiliated hospital revenues	109,789		109,789
Other revenue	35,078	11	35,089
Net assets released from restrictions	104,927	(104,927)	
Total revenues and other support	4,439,793	(4,240)	4,435,553
Expenses:			
Compensation expense	2,506,855		2,506,855
Supplies, services, and other	1,278,017		1,278,017
Depreciation expense	218,070		218,070
Interest expense	74,887		74,887
Total expenses	4,077,829		4,077,829
Net operating results	361,964	(4,240)	357,724
Non-operating activities:			
Investment returns net of endowment spending	(895,974)	(1,282,659)	(2,178,633)
Permanently restricted gifts		102,269	102,269
Other non-operating	9,499	3,490	12,989
Non-operating, net	(886,475)	(1,176,900)	(2,063,375)
Change in net assets	(524,511)	(1,181,140)	(1,705,651)
Net Assets, Beginning of the Year	8,371,599	9,378,506	17,750,105
Net Assets, End of the Year	\$ 7,847,088	\$ 8,197,366	\$ 16,044,454

Washington University Consolidated Statements of Cash Flows Years Ended June 30, 2023 and 2022

(thousands of dollars)	2023	2022
Cash flows from operating activities		
Change in net assets	\$ (658,709)	\$ (1,705,651)
Adjustments to reconcile change in net assets to cash		
provided by operating activities		
Realized and unrealized net losses on investments	313,738	1,626,639
Depreciation expense	224,969	218,070
Permanently restricted gifts	(88,345)	(102,269)
Investments received as gifts - not permanently restricted	(5,193)	(18,540)
Proceeds from sales of investments received as gifts	5,193	18,540
Other non-cash adjustments	39,135	44,801
Changes in assets and liabilities		
Accounts and notes receivable, net	15,183	(126,160)
Pledges receivable, net	1,668	14,748
Accounts payable and accrued expenses	24,374	15,173
Deferred revenue and contract liabilities	(5,677)	(30,565)
Other assets and liabilities	 (60,457)	 18,301
Net cash used by operating activities	 (194,121)	 (26,913)
Cash flows from investing activities		
Proceeds from sales and maturities of investments	7,625,584	9,205,245
Purchases of investments	(6,831,465)	(9,748,041)
Purchases of fixed assets	(543,043)	(459,808)
Student loans disbursed	(16,987)	(14,053)
Student loan payments received	15,956	17,691
Other	(288)	
Net cash provided by/(used) in investing activities	249,757	(998,966)
Cash flows from financing activities		
Principal payments of debt	(79,942)	(66,598)
Proceeds from long-term debt issuance	14,340	1,005,877
Contributions restricted for long-term investment	67,097	40,924
Proceeds from sales of investments received as permanently		. //
restricted gifts	24,287	31,000
Other	(3,789)	(10,077)
Net cash provided by financing activities	 21,993	1,001,126
Net increase/(decrease) in cash	 77,629	(24,753)
Cash and cash equivalents		
Beginning of year	 239,191	 263,944
End of year	\$ 316,820	\$ 239,191
Supplemental data	 	
Interest paid in cash	\$ 92,785	\$ 64,384
Noncash activities		
Contributions of securities and other noncash assets	(29,480)	49,540
Net change in accounts receivable for investments	(16,197)	58,440

(All amounts in thousands of dollars)

1. Summary of Significant Accounting Policies

Organization

Washington University in St. Louis (the "university"), is an institution of higher education that, in furtherance of its role as a charitable and educational institution, engages in various activities, including instruction, research and provision of medical care.

Basis of Presentation and Use of Estimates

The consolidated financial statements have been prepared on the accrual basis of accounting. The consolidated financial statements are consolidated to include the accounts of the university and its affiliates. Significant consolidated affiliates include The Barnard Free Skin and Cancer Hospital, Parallel Properties LLC including its affiliates, Washington University Clinical Associates, LLC and associated physician practices, and Washington University Physicians in Illinois, Inc.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, the estimated useful lives of buildings and equipment, the fair value of certain investments (see footnote 2), the degree of precision in calculation of self-insurance reserves and adequacy of allowances for doubtful accounts. Actual results could differ from those estimates.

Certain reclassifications have been made to the 2022 financial statements to conform to the 2023 financial statement presentation. These reclassifications had no effect on changes in net assets.

Net Assets

Resources are recorded based on the absence or existence of donor-imposed restrictions. Descriptions of the net asset categories are as follows:

- Net assets without donor restrictions are free of donor-imposed restrictions. Board-designated endowment funds are also included within net assets without donor restrictions.
- Net assets with donor restrictions represent net assets that consist of gifts and related earnings that are subject to donor-imposed restrictions or legal stipulations that have not yet been met by actions of the university and/or passage of time as well as gifts and trusts which, by donor restriction, are required to be held in perpetuity. Net assets required to be held in perpetuity at June 30, 2023 and 2022, are \$2,638,879 and \$2,543,043, respectively.

Revenues from sources other than contributions and investment returns are reported as increases in net assets without donor restrictions. Contributions are reported as increases in the appropriate category of net assets, except that contributions which impose donor restrictions that are met in the same fiscal year they are received are included in revenues

(All amounts in thousands of dollars)

without donor restrictions. Gains and investment income that are limited to specific uses by donor-imposed restrictions are reported as increases in net assets without donor restrictions if the restrictions are met in the same reporting period as the gains and income are recognized, except for gains and investment income earned by investment of donor-restricted endowments. Such amounts remain in net assets with donor restrictions until appropriated for expenditure. When a donor restriction expires due to the passage of time or the university's fulfillment of donor stipulated purpose, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of activities as net assets released from restrictions. Donor restricted gifts that are to be held in perpetuity are reported in the non-operating section of the consolidated statements of activities. Gifts of longlived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the university reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service. Expenses are reported as decreases in net assets without donor restrictions.

The university's net assets as of June 30, 2023 consist of the following:

	Without donor restrictions		-	ith donor	Total
Donor-restricted endowment funds	\$		\$	6,686,908	\$ 6,686,908
Board-designated endowment funds	4,27	9,133		523,273	4,802,406
Investment in plant, net	88	4,026			884,026
Pledges				418,821	418,821
Other donor-restricted				62,950	62,950
Operating and other reserves	2,53	0,634			 2,530,634
	\$ 7,69	3,793	\$	7,691,952	\$ 15,385,745

The university's net assets as of June 30, 2022 consist of the following:

	 thout donor estrictions	 ith donor	Total		
Donor-restricted endowment funds	\$	\$ 7,116,348	\$	7,116,348	
Board-designated endowment funds	4,531,534	594,876		5,126,410	
Investment in plant, net	843,517			843,517	
Pledges		423,296		423,296	
Other donor-restricted		62,846		62,846	
Operating and other reserves	 2,472,037	 		2,472,037	
	\$ 7,847,088	\$ 8,197,366	\$	16,044,454	

Investments

Investment gains (losses) in excess of endowment spending distribution and the unrealized appreciation (depreciation) on investments are reported in the non-operating section of the consolidated statements of activities. Investments acquired by gift or bequest are initially recorded at market or appraised value at the date so acquired.

(All amounts in thousands of dollars)

At June 30, 2023 and 2022, investments include \$577,339 and \$925,978, respectively, purchased with unexpended proceeds from the Series 2020A Missouri Health and Educational Facilities Authority (MOHEFA) taxable bonds issued April 3, 2020 and the Series 2022 taxable revenue bonds issued April 7, 2022. The 2020A MOHEFA funds and the 2022 bond funds may be utilized for the purposes set forth in the relevant bond documents.

Fixed Assets

Fixed assets are stated at cost or at fair market values if received as a gift, less accumulated depreciation, computed on a straight-line basis over the estimated useful lives of the assets. Fixed assets include equipment and other assets acquired through sponsored programs during which title is retained by the resource provider. It is probable the university will be permitted to keep the assets when the program terminates. The cost and accumulated depreciation of fixed assets are removed from the records at the time of disposal. Fixed assets by classification at June 30, 2023 and 2022 consist of the following:

	2023	2022
Construction in progress	\$ 911,778	\$ 550,840
Land and improvements to land	219,694	206,433
Buildings	4,944,844	4,847,183
Equipment	820,403	763,035
Total cost	6,896,719	6,367,491
Accumulated depreciation	(3,330,557)	(3,125,350)
Total fixed assets, net	\$ 3,566,162	\$ 3,242,141

Collections

In addition to the Mildred Lane Kemper Art Museum, the university archives rare book collections, works of art, literary works, historical treasures and artifacts. These collections are protected and preserved for public exhibition, education, research and the furtherance of public service. Proceeds from the sale of deaccessioned items are used to acquire new collections. Accordingly, such collections are not recognized or capitalized for financial statement purposes.

Leases

The university determines if an arrangement is or contains a lease at inception based on whether the contract conveys the right to control the use of identified property, plant, or equipment in exchange for consideration. The university has both leases under which it is obligated as a lessee and leases for which it is the lessor. Operating leases in which the university is a lessee are included in right-of-use (ROU) assets and lease liabilities on the consolidated statements of financial position. The university has elected the short-term lease exception under ASC 842 for all leases, and therefore, leases with an initial term of 12 months or less are not included on the consolidated statements of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. The interest rate implicit in lease contracts is typically not readily determinable, and as such, the university uses its collateralized borrowing rate using a period comparable with the lease

(All amounts in thousands of dollars)

term in determining the present value of lease payments. The lease term may, at the university's discretion, include options to extend or to terminate the lease that the university is reasonably certain to exercise. Lease expense for lease payments is recognized on a straight-line basis over the lease term within the supplies, services and other line of the consolidated statement of activities. Variable lease payments based on an index or rate, such as the consumer price index, are initially measured using the index or rate in effect at lease commencement. The university has lease agreements with non-lease components that relate to the lease components. The university elected the practical expedient to account for non-lease components and the lease components to which they relate as a single lease component for all leases. Leasing arrangements for which the university is the lessor are not material to the consolidated financial statements.

Financing Receivables

Financing receivables are principally loans made to students or their parents utilizing gifts, endowment payout, and university resources designated for that purpose and from funds provided by the United States government under the Federal Perkins Student Loan program. Loan funds are reported at estimated realizable value, as it is not practical to determine the fair value of loan fund receivables, which include a large component of federally sponsored student loans. Federally sponsored student loans have significant government restrictions as to marketability, interest rates, and repayment terms. Federal funds are ultimately refundable to the government and are recognized as a liability in the consolidated statements of financial position.

The university's loan portfolio includes over 4,100 individual loans and is geographically diverse. Loans are considered past due if the minimum payment is not received within ten days past the due date. At June 30, 2023 and 2022, respectively 94% and 95% of the parent loans and 76% and 77% of the institutional student loans were considered current. Income earned on financing receivables is recorded on an accrual basis.

Other Assets

The university offers deferred compensation plans for eligible faculty and staff. The plans investments are recorded at market value in other assets with an offsetting liability recorded in accounts payable and accrued expenses within the statement of financial position.

Deferred Revenue and Contract Liabilities

Deferred revenue is recognized on an accrual basis when payments for services are received in advance of performance by the university. The principle components of deferred revenue are clinical trial receipts, grants and contracts, and prepaid tuition and housing.

Tuition and Fees

Tuition and fee revenue, net of scholarships and other implicit price concessions, is recognized over-time using the output method of measuring progress in the fiscal year in which the educational programs are conducted. Students are invoiced at the commencement of each academic period. Payment is due when invoiced. The performance obligation, delivery of educational services, is satisfied as services are rendered. If delivery of the performance obligation is not complete as of fiscal year-end, a contractual liability is recorded. The deferred contract liability at June 30, 2023 and 2022 was \$43,286 and \$50,249, respectively, and is

(All amounts in thousands of dollars)

reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Demonstrated financial need is the major criteria for undergraduate students to receive financial aid. Graduate students often receive tuition support in connection with research assistant, teaching assistant and fellowship appointments. Total financial aid granted to students by the university, including aid provided to employees and their dependents, for the years ended June 30, 2023 and 2022, respectively, was \$477,070 and \$458,928.

The table below identifies student aid by type. Scholarships are reported net against tuition in the consolidated statements of activities. Other amounts are reported as expenses.

	 2023	2022		
Scholarships from unrestricted sources Scholarship support from gifts, endowment	\$ 239,871	\$	246,375	
and other restricted sources	 102,799		88,468	
Total scholarships	342,670		334,843	
Employee and dependent tuition benefits	41,643		39,877	
Stipends	91,212		82,732	
Work study	 1,545		1,476	
Total	\$ 477,070	\$	458,928	

Gifts

Gifts, including unconditional promises to give, are recognized as revenues in the period the gift or promise is received. Gifts received for permanent endowments or perpetual trusts are reported as non-operating revenues. Gifts of assets other than cash are recorded at their estimated fair value at the date of gift and, unless instructed otherwise by the donor, are liquidated upon receipt or as soon as practical thereafter.

Conditional gifts and promises to give are not recognized until the conditions on which they depend are substantially met. Gifts, in the form of unconditional promises to give, to be received after one year are discounted at credit-adjusted tax exempt borrowing rates in accordance with fair value accounting. Pledges outstanding are discounted with rates ranging from 0.22% to 2.95%. Amortization of the discount is recorded as gift revenue. The university has received gifts which are recorded as gift revenue in the period the gift was made but are payable over a specified payment schedule of up to 10 years or more. During the gift payment term, the university is exposed to credit risk for the entity or individual that has made the gift. An allowance is made for uncollectible unconditional promises to give based upon management's judgment, past collections experience and other relevant factors.

(All amounts in thousands of dollars)

A summary of pledges receivable is as follows:

	2023			2022		
In one year or less	\$	176,583	\$	182,711		
Between two and five years		158,483		155,150		
Over five years		103,681		101,971		
		438,747		439,832		
Less:						
Discount		(11,926)		(8,304)		
Allowance for uncollectible amounts		(8,000)		(8,232)		
Total	\$	418,821	\$	423,296		

Grants and Contracts

The university receives grant and contract revenue from governmental and private sources. Revenue associated with the direct costs of sponsored programs is generally recognized as the related costs are incurred. At contract inception, the university determines whether the goods or services to be provided are to be accounted for as a single performance obligation or as multiple performance obligations. If multiple performance obligations are identified, the university generally uses the cost plus a margin approach to determine the relative standalone selling price of each performance obligation. Revenue from these contracts is earned over-time. Invoicing of the customer, if required, will generally be in accordance with terms of the contract with payment due when invoiced. Generally, the time between the receipt of payment and the transfer of goods and service under these contracts is less than one year.

The university records revenue without donor restrictions upon its recovery of direct and indirect costs applicable to those sponsored programs that provide for the full or partial reimbursement of such costs. Most grants awarded to the university by government agencies are conditional contributions. The principle condition attached to these awards is that the university must incur costs in accordance with the Office of Management and Budget's uniform guidance before costs can be reimbursed. Total amounts promised under these grants for which conditions have not yet been fulfilled are approximately \$1,549,759 and \$1,086,536 at June 30, 2023 and June 30, 2022, respectively. The recovery of indirect costs, also referred to as facilities and administrative costs is based on negotiated rates and represents recoveries of facilities and administrative costs incurred under grants and contracts agreements. Recovery of facilities and administrative costs of federally sponsored programs is at rates negotiated with the Department of Health and Human Services.

In some cases, the sponsor will prepay amounts in anticipation of costs to be incurred. In those cases, amounts received in excess of costs incurred are recorded as contract liabilities.

Patient Services Revenue

Net patient services revenue is reported at the amount that reflects the consideration to which the university expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payers (including health insurers and government programs),

(All amounts in thousands of dollars)

and others. Generally, the university bills the patient and third-party payers several days after the services are performed. Revenue is recognized as performance obligations are satisfied.

Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges which provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Amounts receivable under physician service contracts with affiliated and unaffiliated hospitals are \$72,943 and \$71,137 at June 30, 2023 and 2022, respectively.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, the university has elected to apply the practical expedient provided in FASB ASC 606-10-50-14a, and therefore is not required to disclose the aggregate amounts of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.

Generally patients who are covered by third-party payers are responsible for related deductibles and coinsurance, which vary in amount. The university also provides services to uninsured patients. The transaction price for both uninsured patients, as well as insured patients with deductibles and coinsurance, is estimated based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts and implicit price concessions. university determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. determines its estimate of implicit price concessions based on historical collection experience with these classes of patients using a portfolio approach as a practical expedient. The portfolio approach is being used as there are a large volume of similar contracts with similar classes of customers. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. The effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract Contractual adjustments to patient service revenue were \$2,680,000 and \$2,350,000 for the years ended June 30, 2023 and 2022, respectively.

The university has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. In certain instances, the university may enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract. The university reported patient receivables net of contractual adjustments of \$151,641 and \$179,019, at June 30, 2023 and 2022, respectively.

Auxiliary Enterprises – Sales and Services

Auxiliary enterprises sales and services revenue is primarily earned over-time utilizing the output method of measuring progress. Auxiliary enterprise sales and services contracts will generally constitute a single performance obligation as there is a single promise. This revenue is composed primarily of on and off campus housing charges, dining services, and parking and transportation fees with separate contracts for each type of service. Housing, dining services and parking fees are invoiced to undergraduate students at the beginning of each academic

(All amounts in thousands of dollars)

period. Payment is due upon invoice issuance. Graduate students and undergraduates who live off campus sign rental agreements providing for monthly rent payments. Each contract for services in this category has a duration of one year or less. A contract liability is recorded for the delivery of performance obligations that is not completed prior to the fiscal year end.

Educational Activities – Sales and Services

Clinical trial revenue is earned over-time as the university provides services. The transaction price is negotiated with the customer and is usually based on standard rates for clinical services and the expected cost to complete the contract. Payment terms under these contracts vary but generally provide for the right to invoice the customer as work progresses, either based on units performed or the achievement of billing milestones. The university has determined that an input method using costs incurred as a basis to estimate revenue earned best depicts the pattern of transfer of control to the customer. In those limited cases where prepayments are significant, revenue is deferred until earned and a contract liability is recorded. Such amounts are reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Contracts in other educational sales and services cover a broad range of activities including laboratory services, executive education program fees and royalties. Revenue from the contracts in this category is earned over time as services are rendered. The measure of progress varies according to the nature of the services provided. Invoicing to customers is performed in the cadence required under the contracts and amounts invoiced generally are considered due upon receipt. Accruals for services provided but not yet invoiced are recorded at year end. Fees for executive education programs are often received in advance of the program and represent a contract liability. Such amounts are reported as deferred revenue and contract liabilities in the consolidated statement of financial position.

Affiliated Hospital Revenues

Affiliated hospital revenue is earned over-time as the various services are provided as an integrated performance obligation as more fully described in footnote 13. The measure of progress towards completion of those obligations is based on the day-to-day operations of the university's School of Medicine and the affiliated hospitals. Payments are received under the agreement semiannually. Amounts receivable under the agreement are \$88,097 and \$39,202 at June 30, 2023 and 2022 respectively.

Operating Results

The university's measure of operations as presented in the consolidated statements of activities includes income from tuition and fees, grants and contracts, medical services, contributions for operating programs, the endowment spending distribution and other revenues. Operating expenses are reported on the consolidated statements of activities as incurred for employee compensation, depreciation, interest, and supplies, services and other. Operating results exclude investment gains (losses) except for the portion of gains utilized for the endowment spending distribution, contributions to be held in perpetuity, and other non-operating amounts.

(All amounts in thousands of dollars)

Split-Interest Agreements

The university's split-interest agreements with donors consist primarily of charitable gift annuities and irrevocable charitable remainder trusts for which the university serves as trustee. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements. Contribution revenues for charitable gift annuities and charitable remainder trusts are recognized after recording liabilities for the present value of the estimated future payments to be made to the respective donors and/or other beneficiaries. The discount rate used is based on rates in existence at the date of the gift. For new gifts received during fiscal year 2023, the discount rate is the standard IRS discount rate. The discount rate used in 2022 was a credit-adjusted rate. The rates used range from 1.4% to 5.0% for 2023 and 0.67% to 2.25% for fiscal year 2022. Annually, the university records the change in value of split-interest agreements by recording at fair value the assets that are associated with each trust and recalculating the liability for the present value of the estimated future payments to be made to the donors and/or other beneficiaries. For the years ending June 30, 2023 and 2022, the change in fair value was an increase of \$6,474 and \$3,502, respectively. As of June 30, 2023 and 2022, the university's liability under charitable gift annuities was \$16,580 and \$17,141, respectively.

Cash and Cash Equivalents

The university considers cash on hand and in banks and all highly liquid financial instruments with an original maturity of 90 days or less, except those amounts assigned to and invested by its investment managers, which amounts are classified as investments, to be cash and cash equivalents.

Income Taxes

The university is exempt from federal income taxes under Section 501 (c)(3) of the Internal Revenue Code except to the extent the university has unrelated business income, or consolidated for-profit affiliates incur taxes. There was no significant provision for income taxes in the current year. Management believes the university has no uncertain tax positions that result in material unrecognized tax expense/benefits.

2. Fair Value

The university follows FASB guidance for fair value measurements. This guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The FASB guidance establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the university and unobservable inputs reflect the university's assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

(All amounts in thousands of dollars)

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the university for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

- Level 1 Quoted prices in active markets for identical assets or liabilities, such as exchange traded equity securities.
- Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities. Examples of Level 2 include U.S. Treasury securities and corporate bonds.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table presents the financial instruments carried at fair value as of June 30, 2023, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$880,691.

_	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2023
Investments					
Public equity					
Domestic	\$ 163,517	\$	\$ 20,675	\$ 499,195	\$ 683,387
International	156,593			2,033,971	2,190,564
Fixed income - Nominal		1,298,983			1,298,983
Absolute return			476	672,715	673,191
Private capital			244,918	7,142,353	7,387,271
Short-term investments	378,660	5,226			383,886
Real assets	28,054		72,155	838,494	938,703
Other investments	621,067	23,093	63,759	165	708,084
Total investments at fair value	1,347,891	1,327,302	401,983	11,186,893	\$ 14,264,069
Investments not reported at fair value					
Affiliates - Equity basis Accrued investment income					40,723 6,779
Total investments	\$ 1,347,891	\$ 1,327,302	\$ 401,983	\$ 11,186,893	\$ 14,311,571

The following table presents the financial instruments carried at fair value as of June 30, 2022, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient

(All amounts in thousands of dollars)

under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$896,537.

	 Quoted Prices in Active Markets (Level 1)	Other Observable Inputs (Level 2)	Significant nobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2022
Investments					
Public equity					
Domestic	\$ 230,728	\$	\$ 21,759	\$ 1,020,202	\$ 1,272,689
International	97,133			1,746,292	1,843,425
Fixed income - Nominal		1,256,010			1,256,010
Absolute return				667,558	667,558
Private capital			328,880	7,816,548	8,145,428
Short-term investments	219,104	4,408			223,512
Real assets	17,459		20,134	863,633	901,226
Other investments	 962,546	 3,663	 60,141	 32,119	 1,058,469
Total investments at fair value	1,526,970	1,264,081	430,914	12,146,352	15,368,317
Investments not reported at fair value Affiliates - Equity basis Accrued investment income					 44,909 3,458
Total investments	\$ 1,526,970	\$ 1,264,081	\$ 430,914	\$ 12,146,352	\$ 15,416,684

Beneficial interests in perpetual trusts held by third parties are valued at the present value of the future distributions expected to be received over the term of the agreement.

Following is a description of the university's valuation methodologies for assets and liabilities measured at fair value. The methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the university believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Fair value for Level 1 is based upon quoted prices in active markets that the university has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. The university does not adjust the quoted price for such assets and liabilities.

Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers.

Fair value for Level 3 is based on valuation techniques that use significant inputs that are unobservable as they trade infrequently or not at all. Trustees determine the valuation for beneficial interest trusts and split-interest agreements. Strategic real estate is valued at historical cost and is evaluated annually for impairment.

(All amounts in thousands of dollars)

Investments measured at net asset value primarily consist of the university's ownership in alternative investments (principally limited partnership interests in absolute return, private capital investments, real assets, and other similar funds). The fair values (Net Asset Value ("NAV") or partner's capital per share) of the securities held by limited partnerships that do not have readily determinable fair values are determined by the respective general partners and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investments, the fair value is determined by the general partners taking into consideration significant unobservable inputs including, among other things, the cost of the investments, prices of recent significant placements of investments of the same issuer, and subsequent developments concerning the companies to which the investments relate. Excluding the cost of the investment, significant increases or decreases in the remainder of those inputs could result in a significantly higher or lower fair value measurement. The university has performed due diligence with respect to these investments to ensure NAV or partner's capital per share is an appropriate measure of fair value as of June 30. NAVs are calculated by the investees in a manner consistent with generally accepted accounting principles for investment companies.

Significant terms of agreements with external investment managers or funds by major classes of investments are provided in the following tables.

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2023:

Investments	Fair Value June 30, 2023	Unfunded Commitment (1	Remaining) Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$ 2,873,951	\$	No Limit	Daily to annually, with same day-180 day notice	Lock-up provision periods range from none to 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments	1,682,869		No Limit	Daily, 1-2 days notice	No lock-up provision
Absolute return	673,191		No Limit	Quarterly to semi- annually with 45 – 180 days notice	Lock-up provision periods range from none to 3 years. Certain investments include side pockets subject to external manager's discretion.
Private capital	7,387,271	1,696,758	0 - 26 Years	Not eligible for redemption	Not redeemable
Real assets	938,703	307,701	o - 11 Years	Not eligible for redemption	Not redeemable
Total	\$ 13,555,985	\$ 2,004,459			

(All amounts in thousands of dollars)

Footnote (1): Includes \$15 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2022:

Investments	Fair Value June 30, 202	Unfunded 2 Commitment (Remaining 1) Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$ 3,116,114	4 \$	No Limit	Daily to annually, with same day-180 da notice	Lock-up provision periods range from none to a: 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments	1,479,52	2	No Limit	Daily, 1-2 days notice	No lock-up provision
Absolute return	667,558	3	No Limit	Quarterly to semi-annually with 45 – 180 days notice	Lock-up provision periods range from none to 3 years. Certain investments include side pockets subject to external manager's discretion.
Private capital	8,145,428	3 1,686,311	0 - 27 Years	Not eligible for redemption	Not redeemable
Real assets	901,220	397,436	o - 11 Years	Not eligible for redemption	Not redeemable
Total	\$ 14,309,848	\$ 2,083,747	_		

Footnote (1): Includes \$15 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

Public Equities

Public equities include investments in publicly-traded securities in domestic, developed international, emerging, and frontier markets. The majority of assets are held in pooled commingled funds which are valued at NAV as described above. Investments held in custody

(All amounts in thousands of dollars)

accounts are valued at quoted market price in accordance with Level 1 and Level 2 valuation techniques as described above.

Fixed Income and Short-Term Investments

Investments in this class include domestic and international nominal fixed income instruments. Fixed income investments are held principally as liquid vehicles for operating needs and as a source of diversification. A significant component of non-endowment fixed income investments is held in highly liquid funds. The valuation of these funds is determined using a market approach in accordance with the techniques for Level 2 as described above.

Absolute Return

Investments in absolute return are typically held in commingled funds that employ various uncorrelated investment strategies including but not limited to equity hedged and event driven. These funds are valued at net asset value as described above.

Private Capital

Investments in private capital strategies are made in targeted categories including growth equity, venture capital, distressed credit, and corporate finance. The majority of these assets are in non-redeemable drawdown fund structures and distributions are received as underlying investments are liquidated. These funds are primarily valued at net asset value as described above.

Real Assets

Investments in the real assets class are made in targeted categories. The majority of these assets are held in non-redeemable drawdown fund structures that invest primarily in real estate and natural resources. These funds are primarily valued at net asset value as described above.

Level Three

The following tables roll forward the consolidated statement of financial position amounts for financial instruments classified by the university within Level 3 of the fair value hierarchy defined above for the years ended June 30, 2023 and 2022.

]	Balance		t Realized Unrealized	chases, Sales Settlements		ransfers n/(out) of		Balance
	Jun	e 30, 2022	Gai	ns (Losses)	Net	Le	evel 3, net	Jun	e 30, 2023
Investments (by strategy) Private capital Real assets Absolute return Public equity Other investments	\$	328,880 20,134 21,759 60,141	\$	(97,330) (438) (44) (1,084) 6,220	\$ 8,368 7,871 (1,363)	\$	5,000 44,588 520 (1,239)	\$	244,918 72,155 476 20,675 63,759
Total	\$	430,914	\$	(92,676)	\$ 14,876	\$	48,869	\$	401,983

(All amounts in thousands of dollars)

	_	Balance ne 30, 2021	and	t Realized Unrealized ns (Losses)	chases, Sales Settlements Net	Tran in/(o Level	ıt) of	_	Balance e 30, 2022
Investments (by strategy)									
Private capital	\$	254,301	\$	18,356	\$ 56,223			\$	328,880
Real assets		749		(61)	19,446				20,134
Public equity				557			21,202		21,759
Other investments		68,022		(6,656)	 (45)		(1,180)		60,141
Total	\$	323,072	\$	12,196	\$ 75,624	\$	20,022	\$	430,914

The amount of realized and unrealized gains (losses) for Level 3 investments for the period included in net assets attributable to the change in unrealized gains or losses relating to assets still held at June 30, 2023 and 2022 respectively, reported as investment returns net of endowment spending in the consolidated statements of activities by type of investment is:

	2023				
Private capital	\$	(46,968)	\$	18,587	
Real assets		(1,196)		(959)	
Absolute Return		(44)			
Public equity		(1,083)		557	
Other investments		1,837		(7,760)	
Total	\$	(47,454)	\$	10,425	

3. Investment Return

The following summarizes the return on investments. Investment income represents earnings on non-endowed funds. Return on investments is presented net of investment management fees. Certain investments, including some but not all of those in the absolute return and private capital categories, report investment returns net of fees.

	 2023	2022		
Investment income	\$ 72,234	\$	10,530	
Pooled endowment dividends and interest income, net of investment management fees Pooled endowment distribution in excess of income	 (53,596) 623,385		(42,629) 551,994	
Pooled endowment spending distribution	569,789		509,365	
Investment (losses) gains, net Gains distributed as endowment distribution	 (313,738) (623,385)		(1,626,639) (551,994)	
Investment (losses) gains net of endowment spending distribution	(937,123)		(2,178,633)	
Net investment return	\$ (295,100)	\$	(1,658,738)	

(All amounts in thousands of dollars)

4. Endowment

The state of Missouri has adopted legislation that incorporates the provisions outlined in the Uniform Prudent Management of Institutional Funds Act (UPMIFA). The statutory guidelines contained in this legislation relate to the prudent management, investment, and expenditure of donor-restricted endowment funds held by charitable organizations. Additionally, the legislation specifies factors for fiduciaries to consider prior to making a decision to appropriate from or accumulate into an institution's endowment funds.

At June 30, 2023, the university's endowment consists of 4,334 individual donor-restricted endowment funds and Board of Trustees or management-designated endowment funds for a variety of purposes plus split-interest agreements and other net assets where the assets have been designated for endowment. The net assets associated with endowment funds, including funds designated by the Board of Trustees or management to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The university has interpreted Missouri UPMIFA as requiring the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the university classifies as net assets with donor restrictions, (a) the original value of gifts donated to the donor-restricted endowment, (b) the original value of subsequent gifts to the donor-restricted endowment, (c) accumulations to the donor-restricted endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of donor-restricted endowment funds that are not restricted in perpetuity are considered restricted until the donor-imposed stipulations attached to those amounts have been met by actions of the university and/or passage of time and appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA.

Endowment net asset composition, which includes the effect of changes in endowment investments as well as other endowment-related assets and liabilities, by type of fund as of June 30, 2023:

		thout Donor Restriction	Vith Donor Restriction	Total		
Donor-restricted endowment funds Board-designated endowment funds	\$	4,279,133	\$	6,686,908 523,273	\$	6,686,908 4,802,406
Total endowment funds	\$	4,279,133	\$	7,210,181	\$	11,489,314

(All amounts in thousands of dollars)

Changes in endowment net assets for the year ended June 30, 2023:

	hout Donor estriction	 ith Donor estriction	Total		
Endowment net assets, beginning of year	\$ 4,531,534	\$ 7,711,224	\$	12,242,758	
Investment return Net investment income Net decrease in investments (realized and	(21,949)	(30,919)		(52,868)	
unrealized)	(123,111)	(176,607)		(299,718)	
Total investment return	(145,060)	(207,526)		(352,586)	
Gifts Appropriation of endowment assets for	73	92,228		92,301	
expenditure	(233,346)	(336,443)		(569,789)	
Net transfers of funds Allocation of endowment return to treasurer's	34,426	(35,363)		(937)	
investment pool	87,624	(28,762)		58,862	
Other activity	 3,882	14,823		18,705	
Endowment net assets, end of year	\$ 4,279,133	\$ 7,210,181	\$	11,489,314	

Of the amount classified as endowment net assets with donor restrictions, \$4,352,086 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment net asset composition by type of fund as of June 30, 2022:

	 thout Donor Aestriction	 ith Donor estriction	Total		
Donor-restricted endowment funds Board-designated endowment funds	\$ 4,531,534	\$ 7,116,348 594,876	\$ 7,116,348 5,126,410		
Total endowment funds	\$ 4,531,534	\$ 7,711,224	\$ 12,242,758		

(All amounts in thousands of dollars)

Changes in endowment net assets for the year ended June 30, 2022:

	Without Donor Restriction			ith Donor estriction	Total		
Endowment net assets, beginning of year	\$	4,753,833	\$	8,914,248	\$	13,668,081	
Investment return Net investment income Net decrease in investments (realized and		(17,532)		(24,790)		(42,322)	
unrealized)		(650,568)		(956,880)		(1,607,448)	
Total investment return		(668,100)		(981,670)		(1,649,770)	
Gifts Appropriation of endowment assets for		73		73,662		73,735	
expenditure		(209,479)		(299,885)		(509,364)	
Net transfers of funds		156,860		(2,234)		154,626	
Allocation of endowment return to treasurer's							
investment pool		492,955		-		492,955	
Other activity		5,392		7,103		12,495	
Endowment net assets, end of year	\$	4,531,534	\$	7,711,224	\$	12,242,758	

Of the amount classified as endowment net assets with donor restrictions, \$5,072,881 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment by Purpose

The purpose of endowment funds as of June 30, 2023:

	 thout Donor estriction	Vith Donor Restriction	Total		
Restricted for general activities Restricted for student assistance Restricted for buildings and renovations Life income	\$ 2,752,888 1,190,110 336,135	\$ 4,746,584 1,572,685 855,565 35,347	\$	7,499,472 2,762,795 1,191,700 35,347	
Total endowment net assets	\$ 4,279,133	\$ 7,210,181	\$	11,489,314	

The purpose of endowment funds as of June 30, 2022:

	Without Donor Restriction			ith Donor estriction	Total		
Restricted for general activities Restricted for student assistance Restricted for buildings and renovations Life income	\$	2,976,006 1,237,317 318,211	\$	5,122,820 1,583,362 968,473 36,569	\$	8,098,826 2,820,679 1,286,684 36,569	
Total endowment net assets	\$	4,531,534	\$	7,711,224	\$	12,242,758	

(All amounts in thousands of dollars)

Endowment Funds with Deficits

As determined under UPMIFA, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (i.e., deficit). When donor endowment deficits exist, they remain classified as net assets with donor restrictions. Deficits of this nature were immaterial as of June 30, 2023 and 2022. The deficits resulted largely from unfavorable market fluctuations.

Return Objectives and Risk Parameters

The university has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to meet or exceed the return of its policy benchmark, based on the endowment's target allocation applied to the appropriate individual benchmarks. The university expects its endowment funds, over time, to provide an average rate of return that will exceed the sum of inflation and the spending rate. Actual returns in any given year may vary from this amount.

Strategies Employed for Achieving Investment Objectives

To achieve its long-term rate of return objectives, the university relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). The university targets a diversified global asset allocation that places greater emphasis on equity-based and alternative investments to achieve its long-term objectives within prudent risk constraints.

Endowment Spending Allocation and Relationship of Spending Policy to Investment Objectives

The university has an endowment spending distribution policy designed to stabilize annual spending levels and preserve the real value of the endowment over time. Under this policy, earnings of the pooled endowment are distributed at a rate set annually to the schools and other units of the university. Consideration is given to the provisions of UPMIFA in determining the amount to appropriate. This spending rate must fall within the range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For 2023, the spending rate from the pooled endowment was 4.4% of the beginning market value of the pooled endowment. The spending rate is funded from current earnings and, in years when current earnings are insufficient, from previously accumulated earnings of the endowment.

(All amounts in thousands of dollars)

The university's endowment assets at June 30 are as follows:

	2023	2022
Pooled endowment and other funds	\$ 12,390,790	\$ 13,268,759
Life income trusts and pools	69,602	72,442
Externally administered trusts	33,474	31,655
Separately invested endowment	9,037	7,904
Total	12,502,903	13,380,760
Less: Operating funds invested in pool	(991,129)	(1,098,702)
Net endowment assets	\$ 11,511,774	\$ 12,282,058

The amounts above include term endowments of \$132,188 and \$142,691 as of June 30, 2023 and 2022, respectively.

5. Liquidity and Availability of Resources

At June 30, 2023 and 2022, the university's financial assets available for general expenditures within one year of the balance sheet date are as follows:

	 2023	2022
Total assets at year end	\$ 19,792,327	\$ 20,436,866
Less:		
Accounts and notes receivable due in more than one year	(92,742)	(96,297)
Pledges receivable unavailable for general expenditure	(294,173)	(315,600)
Donor-restricted endowment funds	(6,831,617)	(7,279,612)
Board-designated endowment funds	(4,680,157)	(5,002,446)
Other long-term investments	(1,783,702)	(2,225,426)
Right-of-use assets	(93,447)	(76,116)
Other assets	(362,291)	(329,870)
Fixed assets	 (3,566,162)	 (3,242,141)
Total financial assets available within one year	\$ 2,088,036	\$ 1,869,358

The university's endowment funds consist of donor-restricted and board-designated endowment funds. As described in Note 4, the university has an endowment spending distribution policy with a spending rate range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For fiscal year 2024, the Board of Trustees approved a spending rate which will generate an endowment payout equaling or exceeding that of fiscal year 2023, including an allocation to the treasurer's investment pool, which will be available for operations during fiscal year 2024.

In addition to these available financial assets, the university's annual expenditures will be primarily funded by current year operating revenues including tuition, patient services income, and sponsored research income. As part of the university's liquidity management, a policy is in place to structure its financial assets to be available as general expenditures, liabilities, and other obligations come due. The university also invests cash in excess of daily requirements in

(All amounts in thousands of dollars)

short-term investments. Furthermore, although the university does not intend to spend from its board-designated endowment funds other than amounts appropriated for general expenditure as part of its annual budget approval and appropriation process, amounts from its board-designated endowment that are free from investment restrictions could be made available if necessary. Other long-term investments are primarily composed of amounts designated by the university as reserves. Such investments are without donor restriction and could be drawn upon in the event of extreme stress. In the event of an unanticipated liquidity need, the university could also draw upon \$350,000 of available lines of credit at June 30, 2023.

6. Accounts and Notes Receivable

Accounts and notes receivable at June 30 were as follows:

	 2023	2022		
Patient services	\$ 526,077	\$	486,749	
Student and parent loans			40.004	
Parent loan fund	46,654		43,204	
Government student loans	7,142		10,773	
Institutional student loans	16,672		17,792	
Due from affiliate hospitals	190,783		151,599	
Sponsored project receivables	158,210		182,629	
Other	 159,244		130,957	
	1,104,782		1,023,703	
Less: Allowance for contractual adjustments				
and doubtful accounts	 (381,567)		(314,135)	
Total	\$ 723,215	\$	709,568	

(All amounts in thousands of dollars)

7. Notes and Bonds Payable

Outstanding principal on bonds and notes payable at June 30, 2023 and 2022 consists of the following:

	Rates at	Motoritor	2222	2222
	June 30, 2023	Maturity	2023	2022
Missouri Health and Educational Facilities Authors \$88,000 of 2000B and C Series	•			
Variable Rate Bonds, due in full	0.63% - 4.00%	March 1, 2040	\$ 88,000	\$ 88,000
\$25,135 of 2003B Series Variable Rate Bonds, due in full	0.65% - 4.00%	February 15, 2033	25,135	25,135
\$77,495 of 2011C Series Revenue Bonds due serially from November 15, 2012 to November 15, 2037	0.75% - 5.06%	November 15, 2037	44,740	47,215
\$200,785 of 2012A Series Revenue Bonds due serially from February 15, 2023 to February 15, 2047	2.39% - 3.69%	February 15, 2047	180,785	200,785
\$150,000 of 2014A Series Revenue Bonds due in full	4.07%	October 15, 2044	150,000	150,000
\$402,920 of 2016A Series Revenue Bonds due in full January 15, 2036 (\$109,300) and January 15, 2046 (\$293,620)	3.47% - 3.65%	January 15, 2036 and 2046	402,920	402,920
\$272,750 of 2016 B Series Revenue Bonds due in full	3.09%	September 15, 2051	272,750	272,750
\$375,000 of 2017 A Series Revenue Bonds, due in full	3.65%	August 15, 2057	375,000	375,000
\$450,000 of 2020 A Series Revenue Bonds, due in full	3.23%	May 15, 2050	450,000	450,000
Other Bonds:				
\$131,435 of 2015A Series Taxable Bonds due in full	3.79%	October 15, 2055	131,435	131,435
\$1,000,000 of 2022 Series Taxable Bonds, due in full	3.52% - 4.35%	April 15, 2054		
on April 15, 2054 and April 15, 2122		and 2122	1,000,000	1,000,000
Other notes payable with various maturities			153,484	196,611
Total outstanding notes and bonds payable			3,274,249	3,339,851
Unamortized original issue premiums/discounts and cost of issuance, net $$			(14,774)	(15,250)
Total			\$ 3,259,475	\$3,324,601

Bonds payable are redeemable at the option of the university at various times from 2023 through 2122. The university is required to maintain certain ratios and comply with other restrictive covenants principally that the university maintains a ratio of expendable financial resource to bonds and notes payable of at least 1.25 times. The university is in compliance with this covenant. During 2023 and 2022, interest, accretion of debt discount and related fees incurred on notes and bonds payable totaled \$116,923 and \$84,511, respectively.

(All amounts in thousands of dollars)

Maturities on notes and bonds payable for the next five fiscal years are as follows:

2024	\$ 2,577
2025	16,967
2026	134,837
2027	32,522
2028	2,607
Thereafter	3,084,739

The university has other lines of credit, which generally expire annually, aggregating to \$350,000, of which \$350,000 is available at June 30, 2023. The university expects that these lines of credit will be renewed but can make no assurances.

8. Operating Leases

The university and its consolidated affiliates primarily lease laboratories, office space, and medical offices for educational, research, and patient care purposes under operating leases expiring through fiscal 2033. At June 30, 2023 and 2022, the weighted average remaining lease term was 5.8 and 6.0 years and the weighted average discount rate was 3.65% and 3.05%, respectively. Lease expense is included in supplies, services, and other on the consolidated statement of activities.

The undiscounted cash flows due by fiscal year related to significant non-cancelable operating leases with initial terms in excess of one year as of June 30, 2023, along with a reconciliation to the discounted amount recorded as of June 30, 2023 were as follows:

2024	\$ 24,314
2025	21,563
2026	20,589
2027	16,324
2028	13,230
Thereafter	 18,815
Total minimum lease payments	\$ 114,835
Less: Imputed interest	(10,748)
Total lease liabilities	\$ 104,087

9. Derivative and Other Financial Instruments

The university utilizes derivative instruments including futures, swaps, and options, to manage market risk, to provide temporary investment exposure in stocks and bonds, and to manage currency and interest rate exposures. When directly implementing a derivative strategy, the university uses a third party manager to execute, settle and manage the positions on a non-discretionary basis. These contracts are valued at periodic intervals such as daily, monthly, and

(All amounts in thousands of dollars)

quarterly as well as at June 30, with the resulting changes in the values of the contracts either added to or deducted from the university's custodial account. Gains or losses from these derivative instruments are reported as realized and unrealized gains or losses in the consolidated statements of activities. Indirect strategies in derivatives held by limited partnerships and commingled investment trusts in which the university invests pose no off-balance sheet risk to the university due to the limited liability structure of the investments. Derivatives are also used to manage operating expenses but are not material to the consolidated financial statements. No derivative contracts are designated as hedges for accounting purposes.

10. Functional Expenses

Operating expenses are reported on the consolidated statements of activities in natural categories. Expenses reported by functional categories include allocations of costs for operation and maintenance of plant, interest on indebtedness and depreciation expense. Operation and maintenance of plant and depreciation are allocated to functional categories largely based on square footage. Interest expense is allocated based on specific identification of the uses of debt proceeds. Instruction expenses include instruction, departmental research and patient care costs.

Operating expenses by functional and natural classification for the year ended June 30, 2023 are as follows:

	mpensation ad benefits	Supplies, rvices and other	Dej	preciation	I	nterest	Total
Instruction	\$ 1,668,440	\$ 972,454	\$	69,197	\$	33,256	\$ 2,743,347
Research	435,867	279,356		67,630		17,873	800,726
Academic Support	367,454	54,389		23,522		12,275	457,640
Student Services	65,834	66,591		6,179		2,910	141,514
Institutional Support	186,142	38,710		16,630		2,078	243,560
Auxiliary Enterprises	20,971	58,700		41,612		25,154	146,437
Other	 25,603	11,309		199		192	37,303
Total	\$ 2,770,311	\$ 1,481,509	\$	224,969	\$	93,738	\$ 4,570,527

Operating expenses by functional and natural classification for the year ended June 30, 2022 are as follows:

	mpensation nd benefits	Supplies, rvices and other	Dej	preciation	1	nterest	Total
Instruction	\$ 1,540,577	\$ 853,231	\$	81,293	\$	22,521	\$ 2,497,621
Research	400,359	236,454		53,147		12,692	702,652
Academic Support	317,319	36,562		34,553		11,443	399,877
Student Services	58,693	47,722		2,373		911	109,699
Institutional Support	145,668	35,268		6,541		691	188,168
Auxiliary Enterprises	18,121	53,117		37,904		26,481	135,624
Other	26,118	15,663		2,260		147	 44,188
Total	\$ 2,506,855	\$ 1,278,017	\$	218,070	\$	74,887	\$ 4,077,829

(All amounts in thousands of dollars)

11. Commitments and Contingencies

At June 30, 2023 and 2022, the university had outstanding commitments under certain construction contracts in the amount of \$248,572 and \$507,830, respectively.

The university maintains a self-insurance program for professional liability at the Medical School and a separate program for Washington University Physicians in Illinois. This program is supplemented with commercial excess insurance above the university's self-insurance retention. Funding for the program reserves is based on claims made. The assets supporting the funded reserve are reported as investments in the consolidated statements of financial position. The university also accrues for an estimate of claims incurred but not reported. Reserves, funded and unfunded, are based upon actuarial studies and represent undiscounted estimated claims and related costs. The total self-insurance reserves at June 30, 2023 and 2022, respectively, were \$104,012 and \$110,170. Self-insurance reserves are necessarily estimates based on historical loss experience and other factors, and while management believes that the reserves are adequate, the ultimate liabilities may be in excess of or less than the amounts provided.

The university is a party, along with other universities, to an agreement with a reciprocal risk retention group for purposes of obtaining general liability and auto liability insurance coverage in excess of a pre-determined retention level. Under the terms of these agreements, the university can be called upon to make additional capital contributions. In management's view, any such capital calls would not be material.

The university is involved in various legal proceedings arising in the normal course of operations. Although the outcome of any legal proceeding cannot be predicted with certainty, it is the opinion of the university's management that the outcome of these proceedings individually or in the aggregate, will not have a material adverse effect on the business, consolidated statements of activities, financial position or liquidity of the university.

12. Retirement Plan

The university provides its faculty and staff with a defined contribution (403(b)) retirement savings plan in which employee contributions, university contributions and investment earnings accumulate to assist employees at retirement. Participating employees own individual retirement accounts through the Teachers Insurance and Annuity Association (TIAA) and College Retirement Equity Fund (CREF). Under this arrangement, the university and plan participants make monthly contributions to TIAA-CREF. The amount of contribution made by the university is based on employee's hire date and/or age. Vesting provisions are full and immediate. The university's share of the cost of these benefits in 2023 and 2022 was \$121,010 and \$117,581, respectively.

13. Agreements with Affiliated Hospitals

The university has an affiliation agreement with BJC in relation to Barnes Jewish Hospital (BJH), St. Louis Children's Hospital (SLCH), and Barnes Jewish West County Hospital (BJWCH), collectively the Hospitals, which expires December 31, 2027, but may be canceled upon a one-year written notice by either party. This agreement relates to various operating activities of the Hospitals including Orthopedic Center (OC) in Chesterfield, Siteman Cancer


(All amounts in thousands of dollars)

Center – South County, Center for Advanced Medicine (CAM) in South County, BJH Psychiatric Support Center (PSC), Children's Specialty Care Center in Town and Country, and Children's Specialty Care Center in South County.

Under the terms of the affiliation agreement, the university trains and supervises medical residents and interns and manages certain clinical and research activities of the Hospitals. The Hospitals compensate the university for services provided through a fixed annual base payment (adjusted annually for inflation) plus an additional variable payment based on the combined net operating income of the Hospitals. In addition, the university derives revenue from patient services provided at Barnes-Jewish at St. Peters Hospital under an agreement with that hospital and BJH. Payments to the university under affiliation agreements are reported as affiliated hospital revenue on the consolidated statements of activities (see footnote 1). During 2013, BJH agreed to fund on a cost-reimbursement basis over a period of years, certain expenditures by the university. Payments of \$40,855 and \$56,235 were received or accrued as gifts on the consolidated statements of activities under the agreement during 2023 and 2022, respectively.

14. Subsequent Events

The university has performed an evaluation of subsequent events through October 6, 2023, which is the date the consolidated financial statements were issued.



Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
Research and Development Cluster		<u> </u>		•	
DEPARTMENT OF DEFENSE					
Advanced Research Projects Agency Research and Technology Development	10.010			ė 060 940	ė
Research and Technology Development	12.910 12.910	Columbia University	HR0011-22-2-0022	\$ 360,843 213,882	\$ -
Research and Technology Development	12.910	Vanderbilt University Medical Center	HR00111820001	167,059	-
Defense Advanced Research Projects Agency		•			
Defense Advanced Research Projects Agency	12.RD	Charles River Analytics Inc	N6600121C4013	423,763	-
Defense Advanced Research Projects Agency	12.RD	Teledyne Scientific & Imaging LLC	HR00112290113	82,420	
Defense Intelligence Agency Centers for Academic Excellence	10.509	Georgia Institute Of Technology	Throught or a con-	-0	
Defense Threat Reduction Agency	12.598	Georgia Histitute Of Technology	W911W6-21-2-001	78,595	-
Basic Scientific Research - Combating Weapons of Mass Destruction	12.351			141,402	137,745
Defense Threat Reduction Agency	12.RD	Massachusetts General Hospital	HDTRA122C0006	136,485	-3/1/40
Defense Threat Reduction Agency	12.RD	University Of Pittsburgh	W15QKN1691002	893,635	-
Department of Defense					
Department of Defense	12.RD	Advanced Cooling Technologies	N6833521C0432	3	-
Department of Defense Department of Defense	12.RD 12.RD	Barron Associates BlueHalo	W81XWH22C0068	4,725	-
Department of Defense	12.RD 12.RD	BlueHalo	HM0476-21-C-0004 HM0476-21-C-0017	78,838 39,021	-
Department of Defense	12.RD 12.RD	BlueHalo	HQ0860-21-C-7137	76,875	-
Department of Defense	12.RD	Cornerstone Research Group Inc	W81XWH-22-11062	849	-
Department of Defense	12.RD	Eccalon LLC	47QTCA18DooDK	121,821	-
Department of Defense	12.RD	Johns Hopkins University	X81XWH1620060	(244)	-
Department of Defense	12.RD	Mainstream Engineering Corporation	HQ086023C7520	13,774	-
Department of Defense	12.RD	NervGen Pharma Corp	W81XWH1590001	108,510	-
Department of Defense Department of Defense	12.RD	SARC University Of Pittsburgh	W81XWH1710695	4,688	-
Department of the Air Force, Material Command	12.RD	Oliversity Of Fittsburgh	W81XWH209C003	278,331	-
Air Force Defense Research Sciences Program	12.800			412,743	_
Air Force Defense Research Sciences Program	12.800	Pennsylvania State University	FA95502110202	408,534	_
Air Force Defense Research Sciences Program	12.800	Princeton University	FA95502010241	270,246	-
Air Force Defense Research Sciences Program	12.800	West Virginia University	FA9550-21-1-0088	184,596	-
Air Force Defense Research Sciences Program	12.800	Worcester Polytechnic Institute	FA95502210054	61,448	-
Department of the Navy, Office of the Chief of Naval Research					
Basic and Applied Scientific Research Basic and Applied Scientific Research	12,300 12,300	Indiana University-Purdue University Indianapolis	Noo0142112630	1,427,315	221,074
Basic and Applied Scientific Research	12.300	National Marrow Donor Program	5U24HL13866005	37,767 152	-
Basic and Applied Scientific Research	12.300	University of California, Davis	Noo0141712961	45,814	_
Basic and Applied Scientific Research	12.300	University Of Southern California	N000141812632	53,333	-
National Security Agency					
National Security Agency	12.RD	North Carolina State University	H98230-19-D-0012/0002	127,755	-
National Security Agency	12.RD	North Carolina State University	H98230-l 9-D-00 12/0004LAS	34,064	-
Office of the Secretary of Defense Basic, Applied, and Advanced Research in Science and Engineering	12.630	Advanced Regenerative Manufacturing Institute	F0017/W911NF173003	432,894	
Basic, Applied, and Advanced Research in Science and Engineering	12.630	Battelle Memorial Institute	W911SR-15-2-0001	14,843	_
Basic, Applied, and Advanced Research in Science and Engineering	12.630	University Of Iowa	FA95502010346	13,261	_
U.S. Army Material Command			200	0,	
Basic Scientific Research	12.431			1,950,969	506,117
Basic Scientific Research	12.431	University Of Kentucky	FA9550-21-1-0227	26,487	-
Basic Scientific Research	12.431	University of Michigan	W911NF1810208	64,578	-
Basic Scientific Research Basic Scientific Research	12.431	University of Minnesota University of Southern California	W911NF1810240 W911NF2110327	198,635	-
Basic Scientific Research	12.431 12.431	Virginia Tech	W911NF211032/ W911NF2010141	195,205 81,750	-
U.S. Army Medical Command	12.431	virginia recii	1191111 2010141	01,/30	
Military Medical Research and Development	12.RD			2,884,642	984,108
Military Medical Research and Development	12.420			13,042,834	1,134,656
Military Medical Research and Development	12.420	Children's Hospital Corporation	W81XWH1710532	2,766	-
Military Medical Research and Development	12.420	Cornell University	W81XWH1810667	77,603	-
Military Medical Research and Development Military Medical Research and Development	12.420	Fred Hutchinson Cancer Center	WBLXWH1910674	192,685	-
Military Medical Research and Development Military Medical Research and Development	12.420 12.420	IDBiologics Inc Johns Hopkins University	W81XWH1910405 X81XWH1620060	45,182 15,018	-
Military Medical Research and Development	12.420	Saint Louis University	W81XWH1910117	(19,987)	-
Military Medical Research and Development	12.420	Saint Louis University	W81XWH2010241	67,569	-
Military Medical Research and Development	12.420	The Brigham And Women's Hospital Inc	W81XWH1510269	(899)	-
Military Medical Research and Development	12.420	University Of Alabama Birmingham	W81XWH1720037	12,924	-
Military Medical Research and Development	12.420	University Of Alabama Birmingham	W81XWH2210924	149,155	-
Military Medical Research and Development	12.420	University of Colorado Denver	W81XWH1510504	50,214	-
Military Medical Research and Development Military Medical Research and Development	12.420	University of Illinoi at Urban-Champaign	W81XWH2110062	46,524	-
Military Medical Research and Development Military Medical Research and Development	12.420 12.420	University of Missouri System University Of North Carolina Chapel Hill	W81XWH2110173 W81XWH1010117	39,615	-
Military Medical Research and Development	12.420 12.420	University of Pittsburgh	W81XWH1910117 W81XWH1720073	19,729 195	-
Military Medical Research and Development	12.420	University Of South Carolina	W81XWH1920051	31,064	_
Military Medical Research and Development	12.420	Veterans Research & Education Foundation of St. Louis	W81XWH2010785	81,500	-
Military Medical Research and Development	12.420	Veterans Research & Education Foundation of St. Louis	W81XWH2210602	63,522	-

Cluster Title/Federal Grantor/Program Title	Assistance isting Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
Military Medical Research and Development	12.420	Weill Medical College of Cornell University	W81XWH1810667	110,886	
TOTAL DEPARTMENT OF DEFENSE			,	26,180,405	2,983,700
DEPARTMENT OF EDUCATION Office of Postsecondary Education					
Orieses Programs - Doctoral Dissertation Research Abroad	84.022			40,606	_
Office of Special Education and Rehabilitative Services				4-1	
Education Research, Development and Dissemination Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.305	Indiana University	R305N210035	33,718	-
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities TOTAL DEPARTMENT OF EDUCATION	84.325			238,229 312,553	
DEPARTMENT OF ENERGY					
Department of Energy	0				
Office of Science Financial Assistance Program Office of Science Financial Assistance Program	81.049 81.049	Georgia Institute Of Technology	DE-SC0012577	4,695,568 51,501	312,259
Office of Science Financial Assistance Program	81.049	Iowa State University Of Science And Technology	DE-SC0023495	7,371	-
Office of Science Financial Assistance Program	81.049	Michigan State University	DE-SC0013617	145,233	-
Office of Science Financial Assistance Program Office of Science Financial Assistance Program	81.049 81.049	TDA Research Inc University Of Delaware	DESC0018502 DE-SC0023085/UDR0000327	28,529 50,700	-
Office of Science Financial Assistance Program	81.049	University Of Wisconsin	DE-SC0023085/ CDR000032/ DE-SC0021985	3,363	-
Renewable Energy Research and Development	81.087	•		354,740	-
Renewable Energy Research and Development	81.087	Virginia Polytech Institute and State University	DE-EE0009338	116,224	-
Fossil Energy Research and Development Fossil Energy Research and Development	81.089 81.089	Texas A&M University	DE-EE0032108	1,976,968 86,900	872,901
Stewardship Science Grant Program	81.112	Texas recisity	DE-EE0032100	119,249	-
Stewardship Science Grant Program	81.112	Krell Institute	DENA0003960	38,000	-
Stewardship Science Grant Program	81.112	Texas A&M University	DENA0003841	20,003	-
Advanced Research Projects Agency - Energy Department of Energy	81.135 81.RD	Battelle Memorial Institute	394636	405,349 (1,304)	-
Department of Energy	81.RD	Battelle Memorial Institute	DE-AC05-76RL01830	35,191	-
Department of Energy	81.RD	Fermi National Accelerator Lab	DEACo207CH11359	95,951	-
Department of Energy Department of Energy	81.RD 81.RD	Lawrence Berkeley National Laboratory Lawrence Livermore National Laboratory	DEAC0205CH11231 DEAC5207NA27344	226,751 20.185	-
Department of Energy Department of Energy	81.RD	National Renewable Energy Laboratory	DEAC320/NA2/344 DE-AC36-08GO28308	20,165 41,594	-
Department of Energy	81.RD	Pacific Northwest National Laboratory	DE-AC05-76RL01830	33,371	-
Department of Energy	81.RD	Sandia National Laboratories	1888542	(117)	-
TOTAL DEPARTMENT OF ENERGY DEPARTMENT OF HEALTH AND HUMAN SERVICES				8,551,320	1,185,160
DEFARIMENT OF THE THAND HOMAN SERVICES Administration for Children and Families					
Child Abuse and Neglect Discretionary Activities	93.670	Vision for Children at Risk Inc	PACTSTL	176,835	-
Child Abuse and Neglect Discretionary Activities	93.670			15,384	9,768
Administration for Community Living ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433			436,987	27,949
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	University of Wisconsin, Milwaukee	90IFDV0006	941	-/,949
ACL Assistive Technology State Grants for Protection and Advocacy	93.843	Tulane University	5R01HL12242608	77,519	-
Agency for Healthcare Research and Quality Research on Healthcare Costs, Quality and Outcomes	93.226			1.604.506	066 005
Research on Healthcare Costs, Quality and Outcomes	93.226	Children's Hospital Of Philadelphia (The)	5R01HS02742803	1,624,706 34,021	366,397
Research on Healthcare Costs, Quality and Outcomes	93.226	Denver Health and Hospital Authority	1R01HS029153-01	39,344	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Hunter College, City University of New York	1R01HS028650-01A1	4,967	-
COVID19-Research on Healthcare Costs, Quality and Outcomes Research on Healthcare Costs, Quality and Outcomes	93.226 93.226	Trustees Of Columbia University In the City Of New York University Of Chicago	1R01HS02845401A1 5R01HS02780402	129,685 52,413	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University Of Wisconsin	7R01HS02672405	17,885	_
Centers for Disease Control					
Birth Defects and Developmental Disabilities, Prevention, and Surveillance Birth Defects and Developmental Disabilities, Prevention, and Surveillance	93.073	Johns Hopkins University	5U01DD00129702	281,178	70,088
Blood Disorder Program: Prevention, Surveillance, and Research	93.073 93.080	University of Texas Health Science Center at Houston	NU27DD00020-01-00	20,503 13,864	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	•		1,368,403	84,076
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Emory University	6U54CK000601-02-01	4,896	-
Prevention of Disease, Disability, and Death by Infectious Diseases COVID19-Prevention of Disease, Disability, and Death by Infectious Diseases	93.084 93.084	Johns Hopkins University North Carolina State University	U54CK000617-01-00 5U01CK00058703	36,881 59,029	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	North Carolina State University	5U01CK00058703	14,261	_
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Rush University Medical Center Obligated Group	U54CK000607	15,714	-
Prevention of Disease, Disability, and Death by Infectious Diseases Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Trustees Of The University Of Pennsylvania University Of Iowa	5 U54CK000610-02-00 6U54CK00061301	18,399 80.616	-
Prevention of Disease, Disability, and Death by Infectious Diseases Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.084 93.135	University Of Iowa	6U54CK00061301	1,169,885	-
Injury Prevention and Control Research and State and Community Based programs	93.136			281,869	140,536
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	93.185			773,338	
COVID19-Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects COVID19-Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	93.185	University of Florida	1NU21P0005970100	452,702 100,886	100 :
COVID19-immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects Occupational Safety and Health Program	93.185 93.262	Oniversity of Florida	1102110005970100	100,886 252,559	102,117 58,599
Occupational Safety and Health Program Occupational Safety and Health Program	93.262	Center for Construction Research and Training	U60OH009762	252,559 171,432	50,599
Occupational Safety and Health Program	93.262	Center for Construction Research and Training	U60-OH009762-11	64,768	-
Occupational Safety and Health Program	93.262	The Regents of the University of California	R01OH011661	51,353	-
	93.262 93.262 93.262	The Regents of the University of California The Regents of the University of California University Of Iowa	5R01OH011661 5R01OH01166103 5U19OH00886817	51,353 7,913 274,836	-

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
Childhood Obesity Research Demonstration	93.349			627,866	367,512
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	Children's Hospital Corporation	6NU38OT000288	29,237	-
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	The National Association Of Chronic Disease Directors	5NU38OT0002863	37,333	23,050
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	The National Association Of Chronic Disease Directors	5NU38OT0002864	121,158	42,835
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	The National Association Of Chronic Disease Directors	5NU38OT0002865	48,694	32,586
National Organizations for Chronic Disease Prevention and Health Promotion	93.809	National Association For Chronic Disease Director	5NU58DP00651003	11,474	-
National Organizations for Chronic Disease Prevention and Health Promotion	93.809	National Association For Chronic Disease Director	5NU58DP00651004	53,091	-
National Organizations for Chronic Disease Prevention and Health Promotion Capacity Building Assistance for High-Impact HIV Prevention	93.809 93.834	National Association For Chronic Disease Director	5NU58DP00651005	212,742 922,618	-
Sexually Transmitted Diseases (STD) Provider Education Grants	93.034			738,593	143,996 7,718
Autism and Other Developmental Disabilities, Surveillance, Research, and Prevention	93.998			389,698	7,710
Centers for Disease Control	93.RD			1,244,689	110,732
COVID19-Centers for Disease Control	93.RD			7,126	-
COVID19-Centers for Disease Control	93.RD	Children's Hospital Corporation	75D30120C07725	2,463	-
COVID19-Centers for Disease Control	93.RD	Rainmakers Strategic Solutions LLC	Unknown	3,970	-
Centers for Disease Control	93.RD	St. Louis County	DP18-1817	100,826	63,018
Centers for Disease Control	93.RD	St. Louis County	HE2021-0178	19,036	-
Centers for Disease Control	93.RD	St. Louis County	HE2022-0108	157,833	-
Centers for Disease Control COVID19-Centers for Disease Control	93.RD	St. Louis County University Of Alabama Birmingham	HE2023-0012	106,025	11,466
Centers for Disease Control	93.RD 93.RD	Vanderbilt University Medical Center	75D30120C9617 75D30122C12914	(15,725) 36,900	-
Centers for Disease Control Centers for Disease Control	93.RD 93.RD	Vanderbilt University Medical Center	75D30122C12914 75D30122C14944	102,007	-
Centers for Disease Control	93.RD 93.RD	Wayne State University	WSU22027	46,420	-
Department of Health and Human Services	70	y		40,420	
Department of Health and Human Services	93.RD			22,239	-
Food and Drug Administration					
Food and Drug Administration_Research	93.103	Cumberland Pharmaceuticals	1R01FD00637101A1	15,100	-
Food and Drug Administration_Research	93.103	New York Medical College	5R01FD00636303	6,780	-
Food and Drug Administration_Research	93.103	The Brigham And Women's Hospital Inc	5U01FD00721302	1,100	-
Food and Drug Administration_Research	93.103	Trustees Of Columbia University In the City Of New York	5R01FD00574503	4,872	-
Food and Drug Administration_Research	93.103	University Of Alabama Birmingham	5R01FD006368-02	10,058	-
Health Resources and Services Administration Maternal and Child Health Federal Consolidated Programs		Cure HHT Foundation	ALTH AMONG AN ARRANGE		_
Maternal and Child Health Federal Consolidated Programs Maternal and Child Health Federal Consolidated Programs	93.110 93.110	University of Missouri System	1UP4MC464040100 Unknown	45,067 32,209	-
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	Oniversity of Missouri System	Chkhown	1,335,851	154,911
Rural Health Research Centers	93.155	University of Iowa	2U1CRH20419-12-00	99,486	134,911
Rural Health Research Centers	93.155	University of Iowa	5U1CRH20419-13-00	37,391	-
Rural Health Research Centers	93.155	University of Iowa	5U1GRH07633-14-00	21,218	-
Mental and Behavioral Health Education and Training Grants IMMED Office of the Secretary of Health and Human Services	93.732			960,826	-
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	93.RD	Technical Resources International Inc	HHSO100201400002I	42,821	_
National Institutes of Health					
Environmental Health	93.113			2,507,724	137,371
Environmental Health	93.113	Northwestern University	5R01ES03180903	40,229	-
Environmental Health	93.113	Trustees Of Columbia University In the City Of New York	5R01ES03061603	74,949	-
Environmental Health	93.113	University Of Louisville	5R01ES02984603	117,146	-
Environmental Health	93.113	University Of Maryland University Of Southern California	1R01ES034303-01	36,778	-
Environmental Health Oral Diseases and Disorders Research	93.113 93.121	University Of Southern California	1R01ES03396101	68,544 601,778	-
Oral Diseases and Disorders Research Oral Diseases and Disorders Research	93.121	Case Western Reserve University	2R01DE026923-06A1	6,776	-
Oral Diseases and Disorders Research	93.121	Kaiser Foundation	3U01DE02872702S1	5,770	_
Oral Diseases and Disorders Research	93.121	Research Institute at Nationwide Children's Hospital	7R01DE02829604	21,342	_
Oral Diseases and Disorders Research	93.121	TetraImaging, LLC	1R1DE02972701A1	42,744	-
Oral Diseases and Disorders Research	93.121	University Of Alabama Birmingham	5U19DE028717-03	120,725	60,512
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143			14,969	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Louisville	P42ES023716	80,325	-
Human Genome Research	93.172			8,672,178	2,416,422
Human Genome Research	93.172	California Institute Of Technology	5U24HG00222323	35,770	-
Human Genome Research	93.172	Geisinger Clinic	5R01HG00967104	17,625	-
Human Genome Research	93.172	The Broad Institute Inc	5U24HG010262	119,987	-
Human Genome Research Human Genome Research	93.172	University of California, Santa Cruz University of California, Santa Cruz	3U01HG01097103S1	186,804	-
Human Genome Research	93.172 93.172	University of Camornia, Santa Cruz University Of North Carolina Chapel Hill	5U01HG01097104 2U24HG00965005	328,780 1,217	-
Human Genome Research	93.172	University Of North Carolina Chapel Hill	5U24HG00965006	87,921	-
Research Related to Deafness and Communication Disorders	93.173		332411000903000	5,414,908	475,653
Research Related to Deafness and Communication Disorders	93.173	Boystown National Research Hospital	5R01DC01833004	14,093	
Research Related to Deafness and Communication Disorders	93.173	Cincinnati Children's Hospital Medical Center	5R01DC01786702	2,336	-
Research Related to Deafness and Communication Disorders	93.173	East Carolina University	5R01DC01770202	25,699	-
Research Related to Deafness and Communication Disorders	93.173	Northeastern University	7R01DC01950702	216,167	-
Research Related to Deafness and Communication Disorders	93.173	Ohio State University	5U01DC01892002	129,196	-
Research Related to Deafness and Communication Disorders	93.173	University Of Alabama Birmingham	5R01DC01598005	104,766	-
Research Related to Deafness and Communication Disorders	93.173	University Of Iowa	5R01DC01848803	47,247	-
Research Related to Deafness and Communication Disorders Research Related to Deafness and Communication Disorders	93.173 93.173	University Of Pittsburgh University Of Pittsburgh	2RoDC01304806A1 5R01HD07951208	44,778 53,912	-

Cluster Title/Federal Grantor/Program Title	Listing Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Research Related to Deafness and Communication Disorders	93.173	University of Texas at Dallas	5R01DC01966002	22,555	•
Research Related to Deafness and Communication Disorders	93.173	University of Utah	5R01DC0130002	105,620	_
Research Related to Deafness and Communication Disorders	93.173	Vanderbilt University	2RM1HG009034	64,931	_
Research and Training in Complementary and Integrative Health	93.213	*		2,790,436	73,981
Research and Training in Complementary and Integrative Health	93.213	Yale University	5R01AT01141902	157,002	-
National Center on Sleep Disorders Research	93.233			632,649	-
Mental Health Research Grants	93.242			43,484,207	7,536,808
Mental Health Research Grants	93.242	Allen Institute	1UM1MH13098001	326,740	-
Mental Health Research Grants	93.242	Chapman University	5P50MH09688908	36,591	-
Mental Health Research Grants Mental Health Research Grants	93.242	Childrens Hospital Los Angeles Duke University	7R01MH12146203	137,362	-
Mental Health Research Grants Mental Health Research Grants	93.242	Emory University	1R01MH12983201 1R56MH12901901A1	75,563 16,794	-
Mental Health Research Grants Mental Health Research Grants	93.242 93.242	Emory University Emory University	5R01MH11469205	7,803	-
Mental Health Research Grants	93.242 93.242	Geisinger Clinic	5U01MH11409205 5U01MH119705	232,517	-
Mental Health Research Grants	93.242	Harvard University	1R01MH12949301	248,140	
Mental Health Research Grants	93.242	Icahn School Of Medicine At Mount Sinai	1R01MH13035401	19,803	_
Mental Health Research Grants	93.242	Institute of Mental Hygiene	5P50MH11584304	37,726	_
Mental Health Research Grants	93.242	Kaiser Permanente	5P50MH12621902	3,565	_
Mental Health Research Grants	93.242	Kitware Inc	2R42MH11884503	18,261	_
Mental Health Research Grants	93.242	Mayo Clinic	5R01MH122258	52,214	_
Mental Health Research Grants	93.242	Neurolux	5R44MH114944	115,268	-
Mental Health Research Grants	93.242	New York University	5P50MH11366203	198,661	-
Mental Health Research Grants	93.242	Northwestern University	5R01M12187703	1,060,650	-
Mental Health Research Grants	93.242	Northwestern University	7R01MH11126705S1	20,029	-
Mental Health Research Grants	93.242	Nous Imaging Inc	4R44MH12127602	329,215	-
Mental Health Research Grants	93.242	Nous Imaging Inc	5R44MH12206603	313,285	-
Mental Health Research Grants	93.242	Nous Imaging Inc	5R44MH12456703	76,747	-
Mental Health Research Grants	93.242	Pennsylvania State University	1R01MH13000701	184,856	-
Mental Health Research Grants	93.242	Pennsylvania State University	R56MH126349	197,393	-
Mental Health Research Grants	93.242	Purdue University	5R01MH12621302	237,906	-
Mental Health Research Grants Mental Health Research Grants	93.242	Regents Of The University Of Minnesota Regents Of The University Of Minnesota	5R01MH09677310	813,188	-
Mental Health Research Grants Mental Health Research Grants	93.242	Rutgers The State University Of NJ	5R01MH11696104 5U524MH06845720	46,231	-
Mental Health Research Grants	93.242 93.242	The Miriam Hospital	5U524MH06845720 5R01MH11465705	12,044 1,144	-
Mental Health Research Grants	93.242	The Regents of the University of California	5R24MH12916602	62,616	-
Mental Health Research Grants	93.242 93.242	The Regents of the University of California	7R01MH18221703	391,128	-
Mental Health Research Grants	93.242	The Salk Institute for Biological Studies	1UM1MH13099401	329,340	
Mental Health Research Grants	93.242	Trustees Of Columbia University In the City Of New York	1R01MH12059701	42,592	_
COVID19-Mental Health Research Grants	93.242	Trustees Of Columbia University In the City Of New York	1R01MH120597	(4,940)	_
Mental Health Research Grants	93.242	Trustees Of Columbia University In the City Of New York	5K01MH12231903	36,206	_
Mental Health Research Grants	93.242	Universidad de O'Higgins	5U01MH11550204	2,119	_
Mental Health Research Grants	93.242	Universidad de O'Higgins	5U01MH11550205	50,944	-
Mental Health Research Grants	93.242	University Of California Davis	5R01MH12055504	13,561	-
Mental Health Research Grants	93.242	University Of California Los Angeles	5R01MH10002715	206,906	-
Mental Health Research Grants	93.242	University of Connecticut	7R01MH11831104	12,112	-
Mental Health Research Grants	93.242	University of Illinois Chicago	1R61MH11923701A1	686	-
Mental Health Research Grants	93.242	University of Illinois Chicago	4R33MH119237-02	47,462	-
Mental Health Research Grants	93.242	University Of Maryland	1RF1MH12316301A1	49,824	-
Mental Health Research Grants	93.242	University of Missouri at St. Louis	5R01MH10855904	45,623	-
Mental Health Research Grants Mental Health Research Grants	93.242	University Of North Carolina Chapel Hill University Of Rochester	5U01MH11092505	42,640	-
Mental Health Research Grants	93.242	University Of Rochester	2P50MH106435-06A1 5P50MH10643507	338,274	-
Mental Health Research Grants	93.242 93.242	Yale University	5U01MH12463903	130,321 512,577	
Alcohol Research Programs	93.273	Tale University	300111112403903	2,897,932	108,276
Alcohol Research Programs	93.273	RTI International	1R01AA02704901A1	120,568	-
COVID19-Alcohol Research Programs	93.273	State University Of New York	1R01AA02991401	24,192	_
Alcohol Research Programs	93.273	State University Of New York	5U10AA00840133	1,147,664	_
Alcohol Research Programs	93.273	University of California, San Francisco	5R34AA02798302	3,237	_
Alcohol Research Programs	93.273	University Of Maryland	7R01AA02998902	35,742	-
Alcohol Research Programs	93.273	University of Missouri System	5R01AA02782403	115,638	-
Drug Abuse and Addiction Research Programs	93.279			20,207,167	5,575,505
Drug Abuse and Addiction Research Programs	93.279	Childrens Hospital Los Angeles	5U01DA03692607	404,939	-
Drug Abuse and Addiction Research Programs	93.279	George Washington University	5R01DA054751	161,928	-
COVID19-Drug Abuse and Addiction Research Programs	93.279	Harvard Pilgrim Health Care	1R01DA05513101	78,660	-
Drug Abuse and Addiction Research Programs	93.279	Intra-Cellular Therapies Inc	UG3DA047699	3,486	-
Drug Abuse and Addiction Research Programs	93.279	Intra-Cellular Therapies Inc	1UG3DA04769901	468,516	-
Drug Abuse and Addiction Research Programs	93.279	Johns Hopkins University	5R01DA04209404	19,781	-
Drug Abuse and Addiction Research Programs	93.279	Johns Hopkins University	5R21DA4779502	4,590	-
Drug Abuse and Addiction Research Programs	93.279	Massachusetts General Hospital	5R24DA05198802	12,148	-
Drug Abuse and Addiction Research Programs	93.279	New York University	4UH3CA261067-02 5U24NS11384401	31,498	-
COVID19-Drug Abuse and Addiction Research Programs	93.279 93.279	New York University Ohio State University	5U24NS11384401 5R01DA05302804	587	-
Drug Abuse and Addiction Research Programs		Omo State Omversity		11,356	-
Drug Abuse and Addiction Research Programs		Riccana IIC	1R44DA055161-01	20.400	
Drug Abuse and Addiction Research Programs Drug Abuse and Addiction Research Programs Drug Abuse and Addiction Research Programs	93.279 93.279 93.279	Rissana, LLC RTI International	1R44DA055161-01 5R01DA04401405	20,403 125,925	-

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
Drug Abuse and Addiction Research Programs	93.279	The Miriam Hospital	5R25DA03719007	5,369	
Drug Abuse and Addiction Research Programs	93.279	The Regents of the University of California	1U24DA05532501	70,485	_
Drug Abuse and Addiction Research Programs	93.279	The Regents of the University of California	5U24DA04114708	3,074	_
Drug Abuse and Addiction Research Programs	93.279	University Of Arkansas	1R21DA056835-01	33,079	-
Drug Abuse and Addiction Research Programs	93.279	University Of California Los Angeles	Ro1DA053752	123,423	-
Drug Abuse and Addiction Research Programs	93.279	University Of North Carolina Chapel Hill	5R01DA04787605	13,363	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	3UG1DA01583121S5	123,522	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	5UG1DA01583121	100,038	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286			7,575,929	216,555
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Albany Research Institute	5P41EB01878309	486,511	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Boston Children's Hospital (Inactive)	5R01EB03236602	101,114	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	5R01EB02925904	49,361	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Duke University	7R01EB02943102	35,399	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Georgia Institute Of Technology	1R01EB02985201	117,265	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	New York Medical College	5R01EB02831903	18,034	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Rice University	1R21EB033160-01	26,636	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	TetraImaging, LLC	2R43EB026401-02A1	120,256	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Arkansas	7R01EB02758405	12,039	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Connecticut	5U01HL15634903	3,918	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Delaware	5R01EB02757703	153,347	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Illinois at Urbana-Champaign	5R01EB02865203	27,410	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Texas Southwestern	7R01EB03098702	63,965	
Minority Health and Health Disparities Research	93.307	Paston 9-Visitons Of The University Of Vincinia	rBoxMDoorgoog	2,506,919	258,388
Minority Health and Health Disparities Research Minority Health and Health Disparities Research	93.307	Rector & Visitors Of The University Of Virginia The Brigham And Women's Hospital Inc	5R01MD00770207 5R01MD01168504	33,734	-
Minority Health and Health Disparities Research	93.307	UNandUP, LLC (UN&UP)	1R43MD01409201	10,000	-
Minority Health and Health Disparities Research	93.307 93.307	University Of North Carolina Chapel Hill	1R01MD01510901A1	13,230 60,508	-
Minority Health and Health Disparities Research		University Of North Carolina Chapel Hill	1R21MD01510901A1 1R21MD01646701	27,656	-
Minority Health and Health Disparities Research	93.307	University Of North Caronna Chaper Hill University Of Southern California	5R01MD01040701		-
Minority Health and Health Disparities Research	93.307	University Of Southern California	5R01MD01225205 5R21MD01594502	90,215	-
Trans-NIH Research Support	93.307 93.310	Oniversity of Southern Camorina	5K21WD01594502	9,449 8,192,275	1,185,169
COVID19-Trans-NH Research Support	93.310			875,887	57,113
Trans-NIH Research Support	93.310	Duke University	3UCOD02337504S1	26,460	3/,113
Trans-NIH Research Support	93.310	Duke University	5U2COD02337504	6,979	
Trans-WH Research Support	93.310	Florida State University	1R01MD01740401	127,198	
Trans-NIH Research Support	93.310	Harvard University	5U01HG00753008	54,580	
Trans-NIH Research Support	93.310	Medical College Of Wisconsin	5U24HG010423-04	300,741	
Trans-NIH Research Support	93.310	Regents Of The University Of Michigan	3U2CES03016404S1	12,761	_
Trans-NIH Research Support	93.310	The Board Of Trustees Of The Leland Stanford Junior University	1U54HG012723-01	140,422	
Trans-NIH Research Support	93.310	The Board Of Trustees Of The Leland Stanford Junior University	5U54HG01042604	4,684	
Trans-NIH Research Support	93.310	The Brigham And Women's Hospital Inc	5UH3OD02326806	75,871	_
Trans-NIH Research Support	93.310	The Brigham And Women's Hospital Inc	5UH3OD02326807	287,780	_
Trans-NIH Research Support	93.310	The Regents of the University of California	5U54HL14560804	44,071	
Trans-NIH Research Support	93.310	The Regents of the University of California	5UM1HG011585	101,791	
Trans-NIH Research Support	93.310	University of Connecticut	5U01HL15634903	67,578	_
Trans-NIH Research Support	93.310	University Of Florida	OT2OD033753-01	100,869	_
Trans-NIH Research Support	93.310	University of Melbourne	3R01AG05867604S1	6,719	_
Trans-NIH Research Support	93.310	University of Nevada, Las Vegas	1U01OD03323901	8,721	_
Trans-NIH Research Support	93.310	University Of North Carolina Chapel Hill	5U24DK11620404	270,902	_
Trans-NIH Research Support	93.310	University Of North Carolina Chapel Hill	5U24DK11620405	45,845	_
Trans-NIH Research Support	93.310	University Of North Carolina Chapel Hill	5U24DK11620406	197,041	-
Trans-NIH Research Support	93.310	University of South Florida	1OT2OD032720-01	73,433	-
Trans-NIH Research Support	93.310	University Of Wisconsin	5UH3OD023282	691,240	-
National Center for Advancing Translational Sciences	93.350	•		13,635,158	1,569,021
National Center for Advancing Translational Sciences	93.350	Altamira Therapeutics Inc	1R41TR00324401A1	83,439	-
National Center for Advancing Translational Sciences	93.350	Baylor College of Medicine	1 UG3TR003908	24,891	-
National Center for Advancing Translational Sciences	93.350	Children's Hospital Corporation	5U01TR00262303	102,826	-
National Center for Advancing Translational Sciences	93.350	Duke University	5U01TR00180303	727	-
National Center for Advancing Translational Sciences	93.350	Dystonia Medical Research Foundation	U54TR001456	18,537	-
National Center for Advancing Translational Sciences	93.350	Harvard University	3UL1TR00254104S2	4,046	-
National Center for Advancing Translational Sciences	93.350	Harvard University	5UL1TR00254105	33,396	-
National Center for Advancing Translational Sciences	93.350	Northwestern University	1U01TR00352801	216,225	-
National Center for Advancing Translational Sciences	93.350	Precision Virologics Inc	7R41TR00186902	232	-
National Center for Advancing Translational Sciences	93.350	Seattle Children's Research Institute	1R21TR00405701	4,203	-
National Center for Advancing Translational Sciences	93.350	University of Colorado Denver	5U24TR00230606	25,219	-
National Center for Advancing Translational Sciences	93.350	University Of Iowa	5R21TR00341002	62,457	-
National Center for Advancing Translational Sciences	93.350	Vanderbilt University Medical Center	5U01TR00239802	(166)	-
National Center for Advancing Translational Sciences	93.350	Virginia Commonwealth University	5R21TR00318402	1,559	-
Research Infrastructure Programs	93.351			2,430,580	293,758
Research Infrastructure Programs	93.351	Cornell University	5P40OD01096418	126,673	
21st Century Cures Act - Beau Biden Cancer Moonshot	93-353			7,814,986	2,588
21st Century Cures Act - Beau Biden Cancer Moonshot	93-353	Children's Hospital Of Philadelphia (The)	1U54CA23256801	92,503	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93-353	Duke University	1U2CCA23325401	105,671	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93-353	Fred Hutchinson Cancer Center	5UM1CA15496710	22,034	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Fred Hutchinson Cancer Center	5UM1CA154967-11	3,449	

Section Sect	Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
Memory M		93,353		6UM1CA15496712	5,887	_
Section Control Co				0.15.7		539,588
Description Common Common Common Commo						115,239
Came Traversion Bounds						-
Caucar Caucar of Prevention Research 19,203 Authors State Chemistry Special State Sp			University of Houston	1K21NK020379	,	1 050 050
Cauce Cases and Proventiles Research 1921 1966 1966 1967 196			Arizona State University	2U01CA10700206		1,352,253
Cauce Clause and Preventible Research 19.20 Entire Transpartial Reductal Reload Perfect Research 19.20 Cauce Clause and Preventible Research 19.20 Cauce Claus						_
Concert Case of Promoteries Research \$1.50 School Promoteries Re	Cancer Cause and Prevention Research					-
Cauce Cauce and Precedition Records 9.393 Manufacturetti General Regulat Registration (19.00) 1.00 1.0					110,081	-
Counce Classes and Prevention Research 19.329 Mayor Classes Special Counce Specia						-
Causer Classes and Provention Research 19.000 May Claim 19.000 March Classes STRACTA (SIGNISON) March Classes						-
Concer Cause and Prevention Research 9.0.900 More Clause and Prevention						-
Concer Clause and Provertion Research 93.928 Marie Clause and Provertion Research 93.929 Marie Clause and Provertion Research 93.929 Reference to Marie Clause Clause and Provertion Research 93.929 Reference to Marie Clause Clau						_
Cancer Cancer and Prevention Research 19.202 Northwesters University 250%Catalling 14.00						-
Concert Clause and Provestion Research 9.299 Rockfeller University 1.000 1.0	Cancer Cause and Prevention Research					-
Cancer Canas and Provision Research 50,000 The Respital for six Challeron 50,000 50		93-393				-
Concer Clase and Prevention Rememb \$9,900 Charles (OFTee University Of Pennsylvania \$00.CA/\$190,009.05 \$3,900 Charles (Charles						-
Concert Cause and Prevention Research 93.99 University of Connection 80.0C.Accounts 20.00 10.00						-
Cancer Cause and Prevention Research 93.900 University of Yorth Confident and Charlette \$10.00 Catagogroup 34.00 Cancer Cause and Prevention Research 93.900 University of Yorth Confident \$70.00 Catagogroup 35.004 Cancer Cause and Prevention Research 93.900 University of Yorth Canada \$10.00 Catagogroup 35.004 Cancer Cause and Prevention Research 93.900 University of Utah 20.00 Catagogroup 35.004 Cancer Cause and Prevention Research 93.900 University of Utah 20.00 Catagogroup 35.004 Cancer Cause and Prevention Research 93.900 University of Utah 20.00 Catagogroup 35.004 Cancer Cause and Prevention Research 93.900 Valenting University of Utah 20.00 Catagogroup 20.00 Catag						-
Camer Classe and Pervention Research 93.99 10 10 10 10 10 10 10						-
Cancer Classes and Prevention Research						_
Cancer Cause and Prevention Research						-
Cancer Cause and Prevention Research				5R01CA22564703	35,064	-
Cancer Cause and Prevention Research					36,102	-
Cancer Detection and Diagnosis Research 93.395 Wale Forent University \$80.07.26/2019/305 293.260						-
Cancer Phetection and Diagnosis Research						-
Cancer Detection and Diagnosis Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/09 \$6,564 Cancer Detection and Diagnosis Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/09 \$7,540 Carlor Detection and Diagnosis Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/09 \$7,540 Carlor Detection and Diagnosis Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/09 \$7,640 Carlor Detection and Diagnosis Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/09 \$80,650 Cancer Detection and Diagnosis Research 93.394 Acoustic Research 93.394 Acoustic Research 93.394 Acoustic Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/00 \$80,650 Cancer Detection and Diagnosis Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/00 Acoustic Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/00 Acoustic Research 93.394 Acoustic Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/00 Acoustic Research 93.394 Acoustic Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/00 Acoustic Research 93.394 Acoustic Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/00 Acoustic Research 93.394 Acoustic Range Estimates LLC \$84,4C\3.2076/00 Acoustic Range Estimat			wake Forest University	5K01CA22607803		
Cancer Detection and Diagnosis Research 93.94 Caris Transging 27,640 Cancer Detection and Diagnosis Research 93.94 Memortal Sloan Kettering Cancer Center 380.0CA4425302 63,647 63,64			Acoustic Range Estimates LLC	5R44CA24276402		2,/01,/02
Cancer Detection and Diagnosis Research				2R44CA20680105		_
Cancer Petection and Diagnosis Research	Cancer Detection and Diagnosis Research		Memorial Sloan Kettering Cancer Center			-
Cancer Detection and Diagnosis Research		93-394				-
Cancer Detection and Diagnosis Research 93.394 Sargetta Of The University Of Colorado 11H.GCA6604950 9.657						-
Cancer Detection and Diagnosis Research						-
Cancer Detection and Diagnosis Research						-
Camer Detection and Diagnosis Research						-
Camer Peterdon and Diagnosis Research						_
Camer Peterdion and Diagnosis Research 93,394 University Of California Los Angeles \$10.0249,0903 31,016 \$1.025 \$1.0						-
Camer Petertion and Diagnosis Research 93.394 University Of San Francisco \$8.01CA21214805 \$6.588 Camer Detection and Diagnosis Research 93.394 University Of Texas Southwestern \$0.124.626985 \$5.339 Camer Detection and Diagnosis Research \$9.395 Vanderbilt University Medical Center \$1.24.62698819 (1,180) \$1.24.055 1.417. Camer Textment Research \$9.395 Accuronis Therapeutics \$1.24.62698870 \$1.29.855 1.417. Camer Textment Research \$9.395 Accuronis Therapeutics \$1.24.623985302A \$3.82.325 \$1.417. Camer Textment Research \$9.395 Accuronis Therapeutics \$1.24.623985302A \$3.82.325 \$1.417. Camer Textment Research \$9.395 Accuronis Therapeutics \$1.42.623985302A \$3.82.325 \$1.417. Camer Textment Research \$9.395 Accuronis Therapeutics \$1.42.623985302A \$3.82.325 \$1.417. Camer Textment Research \$9.395 Accuronis Therapeutics \$1.42.623985302A \$3.82.325 \$1.417. Camer Textment Research \$9.395 American College of Radiology \$1.24.623985305 \$0.064 \$1.00.0000 \$1.00.000 \$1.00.000 \$1.00.0000 \$1.00.0000 \$1.00.00					17,006	-
Cancer Petettion and Diagnosis Research 93.394 University of Feas Southwestern 50.24C,08656519 (1,180) Cancer Treatment Research 93.394 Vanderbilt University Medical Center 50.24C,08656919 (1,180) Cancer Treatment Research 93.395 Accuronix Therapeutics 24.4C,082,085302A1 38.235 Accuronix Therapeutics 24.4C,082,085302A1 38.235 Accuronix Therapeutics 24.4C,082,085302A1 38.235 Accuronix Therapeutics 24.4C,082,085303 6.458 Cancer Treatment Research 93.395 Accuronix Therapeutics 54.4C,082,085303 6.458 Cancer Treatment Research 93.395 Annerican College of Radiology 10.24,CA,08060,008IRCC 8.6c2 Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) 10.24,CA,08060,008IRCC 30.6c4 Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) 10.24,CA,08060,008IRCC 30.6c4 Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) 10.24,CA,08060,008IRCC 30.6c4 Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) 10.24,CA,08060,008IRCC 30.6c4 Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) 10.24,CA,08060,0078 10.2						-
Cancer Pretentent Research 93.394 Vanderhilt University Medical Center 5124,CAO8569819 11,1870 1,4173 1,41						-
Cancer Treatment Research 93,395 Accuronix Therapeutics 54,42Ca,298,5303 64,58 Cancer Treatment Research 93,395 Children's Hospital of Philadelphia (The) 54,000,44 10,530 Cancer Treatment Research 93,395 Children's Hospital of Philadelphia (The) 58,000,44 10,530 Cancer Treatment Research 93,395 Children's Hospital of Philadelphia (The) 58,000,44 10,530 Cancer Treatment Research 93,395 Code,44 Cancer Research Group 51,000,480,500 10,322 Cancer Treatment Research 93,395 Code,44 Cancer Research Group 51,000,480,500 10,322 Cancer Treatment Research 93,395 Code,44 Cancer Research Group 51,000,480,500 10,322 Cancer Treatment Research 93,395 Code,44 Cancer Research Group 51,000,480,500 10,322 Cancer Treatment Research 93,395 Code,44 Cancer Research Group Cancer Research Group Cancer Research Group Cancer Treatment Research 93,395 Cancer Treatment Research 93,395 Medical Guidance Systems, LLC 24,402,606,500 10,322 Cancer Treatment Research 93,395 Medical Guidance Systems, LLC 24,402,606,500 10,322 Cancer Treatment Research 93,395 NRG Oncology Foundation Inc Unknown 12,520 5,500,500,500,500 Cancer Treatment Research 93,395 NRG Oncology Foundation Inc Unknown 12,520						-
Cancer Treatment Research			validerbile oliversity inedical center	3024CA06030619		1 /17 225
Cancer Treatment Research			Accuronix Therapeutics	2R41CA23985302A1		-
Cancer Treatment Research 93.395 American College of Radiology 1U2c(A180803004ROC 30.624 Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) 5R01CA4109814 16.350 Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) 5R01CA4109814 16.350 Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) 5R01CA4109814 16.350 Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) 5R01CA4109602 759 Cancer Treatment Research 93.395 Duke University 3U16CA180704051 331.541 Cancer Treatment Research 93.395 ECOG-ACRIN Cancer Research Group 5U10CA18082008 27.922 Cancer Treatment Research 93.395 ECOG-ACRIN Cancer Research Group PU3.000082009 10.322 Cancer Treatment Research 93.395 ECOG-ACRIN Cancer Research Group PU3.000082009 10.322 Cancer Treatment Research 93.395 ECOG-ACRIN Cancer Research Group PU3.000082009 10.322 Cancer Treatment Research 93.395 ECOG-ACRIN Cancer Research Group PU3.000082009 10.322 Cancer Treatment Research 93.395 Doints Hopkins University PU3.000082009 10.322 Cancer Treatment Research 93.395 Johns Hopkins University 5U10CA18082009 10.364 Cancer Treatment Research 93.395 Medical Guidance Systems, LLC 24.4CA106690241 5.466 Cancer Treatment Research 93.395 Medical Guidance Systems, LLC 24.4CA106690241 5.466 Cancer Treatment Research 93.395 Medical Guidance Systems, LLC 24.4CA106690241 5.466 Cancer Treatment Research 93.395 NRG Oncology Foundation Inc U1.000082009 10.00082009 10.00082009 10.00082009 10.000	Cancer Treatment Research			5R42CA23985303		-
Cancer Treatment Research						-
Cancer Treatment Research						-
Cancer Treatment Research 93.395 Children's Hospital Of Philadelphia (The) SROICA21199602 759 331,541 341,041						-
Cancer Treatment Research			Children's Hospital Of Philadelphia (The)			-
Cancer Treatment Research	***************************************					-
Cancer Treatment Research 93.395 ECOG-ACRIN Cancer Research Group 5U10CA18082009 10.322 1.502 1.	Cancer Treatment Research					-
Cancer Treatment Research 93.395 George Washington University R01CA275904 1,772 - Cancer Treatment Research 93.395 Johns Hopkins University 5UMCA13744310 1,364 - Cancer Treatment Research 93.395 Medical Guidance Systems, LLC 2R44CA21068702A1 5,466 - Cancer Treatment Research 93.395 Memorial Sloan Kettering Cancer Center 5U01CA23844402 21,793 - Cancer Treatment Research 93.395 NRG Oncology Foundation Inc Unknown 12,520 5,6 Cancer Treatment Research 93.395 NRG Oncology Foundation Inc UCA18086809 14,669 - Cancer Treatment Research 93.395 NRG Oncology Foundation Inc UCA1808688 4,899 - Cancer Treatment Research 93.395 NRG Oncology Foundation Inc UCA1808688 4,899 - Cancer Treatment Research 93.395 Public Health Institute 5UMICA22882305 9,064 - Cancer Treatment Research 93.395 Public Health Institute 5UMICA22882304 111,591 -	Cancer Treatment Research		ECOG-ACRIN Cancer Research Group	5U10CA18082009		-
Cancer Treatment Research 93.395 Johns Hopkins University 5UMICA19744310 1,364		93-395			23,247	-
Cancer Treatment Research 93.395 Medical Guidance Systems, LLC 2R44(A21068702A1 5,466 Cancer Treatment Research 93.395 Memorial Sloan Kettering Cancer Center 5U01CA23844402 21,793 Cancer Treatment Research 93.395 NRG Oncology Foundation Inc Unknown 12,520 5,6 Cancer Treatment Research 93.395 NRG Oncology Foundation Inc 5U0CA18086809 14,669 - Cancer Treatment Research 93.395 NRG Oncology Foundation Inc UCA1808688 4,899 - Cancer Treatment Research 93.395 Public Health Institute 5UMICA22882305 9,064 - Cancer Treatment Research 93.395 Public Health Institute 7UMICA22882305 9,064 - Cancer Treatment Research 93.395 Public Health Institute 7UMICA22882305 11,691 - Cancer Treatment Research 93.395 Public Health Institute 7UMICA22882304 111,691 - Cancer Treatment Research 93.395 Regents Of The University of Minnesota 2POICA11114216 30,388 - Canc						-
Cancer Treatment Research 93.395 Memorial Sloan Kettering Cancer Center 5U1CA23844402 21.793 - Cancer Treatment Research 93.395 NRG Oncology Foundation Inc Unknown 12,520 5,6 Cancer Treatment Research 93.395 NRG Oncology Foundation Inc 5U1CA18086809 14,669 - Cancer Treatment Research 93.395 NRG Oncology Foundation Inc UCA180868B 4,899 - Cancer Treatment Research 93.395 Public Health Institute 5UM1CA22882305 9,064 - Cancer Treatment Research 93.395 Public Health Institute 7UMICA22882304 114,611 - Cancer Treatment Research 93.395 Public Health Institute U10CA180886 111,593 - Cancer Treatment Research 93.395 Regents Of The University of Minnesota 2P01CA1141216 30,388 - Cancer Treatment Research 93.395 Saint Louis University 1R21CA263428-014 22,225 - Cancer Treatment Research 93.395 Under Children's Research Hospital 1U0.CA180820-014 19,512						-
Cancer Treatment Research 93.395 NRG Oncology Foundation Inc Unknown 12,520 5.5 Cancer Treatment Research 93.395 NRG Oncology Foundation Inc 5U10CA18086809 14,669 - Cancer Treatment Research 93.395 NRG Oncology Foundation Inc UCA180868B 4,899 - Cancer Treatment Research 93.395 Public Health Institute 5UMICA22882305 9,064 - Cancer Treatment Research 93.395 Public Health Institute 7UMICA22882304 114,611 - Cancer Treatment Research 93.395 Public Health Institute U10CA180886 111,593 - Cancer Treatment Research 93.395 Regents Of The University Of Minnesota 2P10CA11141216 30,388 - Cancer Treatment Research 93.395 Saint Louis University 182/CA64282-01A1 22,225 - Cancer Treatment Research 93.395 St. Jude Children's Research Hospital 1U0/CA24657001A1 19,512 - Cancer Treatment Research 93.395 The Brigham And Women's Hospital Inc 3U0/CA180821-09S3 42,606						-
Cancer Treatment Research 93.395 NRG Oncology Foundation Inc 5U10CA18086809 14,669 Cancer Treatment Research 93.395 NRG Oncology Foundation Inc UCA180868B 4,899 Cancer Treatment Research 93.395 Public Health Institute 5UMICA22882305 9,064 Cancer Treatment Research 93.395 Public Health Institute 7UMICA22882304 114,611 Cancer Treatment Research 93.395 Public Health Institute UI OCA180886 111,593 Cancer Treatment Research 93.395 Regents Of The University Of Minnesota 2POICA11141216 30,388 Cancer Treatment Research 93.395 Saint Louis University 1R2ICA265428-01A1 22,225 Cancer Treatment Research 93.395 St. Jude Children's Research Hospital 1UOICA24657001A1 19,512 Cancer Treatment Research 93.395 The Brigham And Women's Hospital Inc 3U10CA180821-0953 42,606						5,952
Cancer Treatment Research 93.395 NRG Oncology Foundation Inc UCA180868B 4,899 - Cancer Treatment Research 93.395 Public Health Institute 5UM1CA22882305 11,611 - Cancer Treatment Research 93.395 Public Health Institute 7UMICA22882304 114,611 - Cancer Treatment Research 93.395 Public Health Institute UIOCA180886 111,593 - Cancer Treatment Research 93.395 Regents Of The University of Minnesota 2POICA11141216 30,388 - Cancer Treatment Research 93.395 Saint Louis University 1R2ICA263428-01A1 22,225 - Cancer Treatment Research 93.395 St. Jude Children's Research Hospital 1UOCA2657001A1 19,512 - Cancer Treatment Research 93.395 The Brigana And Women's Hospital Inc 3UOCA180821-0953 42,606 -						5,95 <u>2</u>
Cancer Treatment Research 93.395 Public Health Institute 5UM1CA22882305 9,064 - Cancer Treatment Research 93.395 Public Health Institute 7UM1CA22882304 114,611 - Cancer Treatment Research 93.395 Public Health Institute U10CA180886 111,593 - Cancer Treatment Research 93.395 Regents Of The University Of Minnesota 2P01CA11141216 30,388 - Cancer Treatment Research 93.395 Saint Louis University 1R21CA265428-01A1 22,225 - Cancer Treatment Research 93.395 St. Jude Children's Research Hospital 1UO1CA24657001A1 19,512 Cancer Treatment Research 93.395 The Brigham And Women's Hospital Inc 3U10CA180821-0983 42,606	Cancer Treatment Research					-
Cancer Treatment Research 93.395 Public Health Institute U10CA180886 111,593 - Cancer Treatment Research 93.395 Regents Of The University Of Minnesota 2PolCA11141216 30.388 - Cancer Treatment Research 93.395 Saint Louis University 1R2ICA26428-01A1 22,225 - Cancer Treatment Research 93.395 St. Jude Children's Research Hospital 1U0ICA24657001A1 19,512 - Cancer Treatment Research 93.395 The Brigham And Women's Hospital Inc 3U10CA180821-09S3 42,606 -					9,064	-
Cancer Treatment Research 93.395 Regents Of The University Of Minnesota 2P01CA11141216 30.388 - Cancer Treatment Research 93.395 Saint Louis University 1R21CA265428-014 22,225 - Cancer Treatment Research 93.395 St. Jude Children's Research Hospital 1U01CA24657001A1 19,512 Cancer Treatment Research 93.395 The Brigham And Women's Hospital Inc 3U10CA180821-09\$3 42,606						-
Cancer Treatment Research 93.395 Saint Louis University 1R21CA263428-01A1 22,225 Cancer Treatment Research 93.395 St. Jude Children's Research Hospital 1U0/CA465700A1 19,512 Cancer Treatment Research 93.395 The Brigham And Women's Hospital Inc 3U0/CA180821-0983 42,606	***************************************					-
Cancer Treatment Research 93.395 St. Jude Children's Research Hospital 1U01CA24657001A1 19.512 - Cancer Treatment Research 93.395 The Brigham And Women's Hospital Inc 3U10CA180821-09S3 42,606 -						-
Cancer Treatment Research 93.395 The Brigham And Women's Hospital Inc 3U10CA180821-09S3 42,606						-
						-
						-
Cancer Treatment Research 93,395 The Brigham And Women's Hospital Inc 5UIoCA18082108 3,153 -	Cancer Treatment Research					-

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
Cancer Treatment Research		The Brigham And Women's Hospital Inc	5U10CA18082109	21,658	
Cancer Treatment Research	93-395 93-395	The Children's Hospital Of Philadelphia	5UM1CA22882302	(90,853)	
Cancer Treatment Research	93-395	The Children's Hospital Of Philadelphia	U10CA180886	22,903	_
Cancer Treatment Research	93.395	The Emmes Company, LLC	2UM1CA12194714	25,128	-
Cancer Treatment Research	93-395	The Emmes Company, LLC	5UM1CA12194716	180,081	-
Cancer Treatment Research	93-395	UNandUP, LLC (UN&UP)	1R43CA23994501A1	42,152	-
Cancer Treatment Research	93.395	University Of Cincinnati	7UG1CA23333804	184,237	-
Cancer Treatment Research	93-395	University Of Miami	7R01CA25398602	507	-
Cancer Treatment Research	93-395	University Of Rochester	1R01CA21489001A1	7,030	-
Cancer Treatment Research	93-395	University Of Rochester	61835	118,995	-
Cancer Treatment Research	93-395	University Of Texas MD Anderson Cancer Center	5R01CA23562204	11,723	-
Cancer Treatment Research Cancer Treatment Research	93-395 93-395	Yale University Yale University	2UM1CA18668906 5UM1CA18668907	248,284 139,780	-
Cancer Biology Research	93-395 93.396	Tale University	50MICA1600690/	9,877,757	260,211
Cancer Biology Research	93.396	Baylor University	7R01CA23964502	9,0//,/3/	200,211
Cancer Biology Research	93.396	Case Western Reserve University	1P01CA24570501	27,691	_
Cancer Biology Research	93.396	Case Western Reserve University	1P01CA24570501A1	59,650	_
Cancer Biology Research	93.396	Case Western Reserve University	5P01CA245705	444,153	_
Cancer Biology Research	93.396	Coriell Institute for Medical Research	5R01CA24423602	162,171	-
Cancer Biology Research	93.396	North Carolina Central University	5R01CA24423602	192,079	-
Cancer Biology Research	93.396	Ohio State University	5P01CA10073018	697,625	-
Cancer Biology Research	93.396	Pennsylvania State University	1R21CA274265-01A1	1,688	-
Cancer Biology Research	93.396	Saint Louis University	R37CA265877	53,620	-
Cancer Biology Research	93.396	Saint Louis University	5R37CA26587702	22,662	-
Cancer Biology Research	93.396	The Board Of Trustees Of The Leland Stanford Junior University	62968987	363,374	-
Cancer Biology Research	93.396	The Regents of the University of California	1U01CA26703101	6,784	-
Cancer Biology Research	93.396	The Regents of the University of California	1U01CA26703102	135,158	-
Cancer Biology Research	93.396	University of California, San Francisco	7R01CA23455304	66,660	-
Cancer Center Support Grants	93-397	0. 77. 1. 7.	TT - 04 - 6 6	8,394,810	130,548
Cancer Center Support Grants	93-397	Case Western Reserve University	5U54CA16306010	15,730	-
Cancer Center Support Grants Cancer Center Support Grants	93-397	Northwestern University University Of North Carolina Chapel Hill	5P50CA221747-05 1P50CA257911-01A1	73,804 49,824	-
Cancer Research Manpower	93-397	University Of North Carolina Chaper Hill	1F50CA25/911-01A1	5,300,196	-
Cancer Control	93.398 93.399	Children's Hospital Of Philadelphia	2UG1CA1899506	(55,558)	-
Cancer Control	93.399	NRG Oncology Foundation	3UG1CA18986706S2	(546)	
Cardiovascular Diseases Research	93.837	Tito oncology Foundation	3001011090070002	31,635,153	2,496,072
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	1R01HL16456101	33,015	
Cardiovascular Diseases Research	93.837	Cedars Sinai Medical Center	5R01HL14994604	20,335	-
Cardiovascular Diseases Research	93.837	Emory University	5R01HL12239207	42,762	-
Cardiovascular Diseases Research	93.837	HealthCore Inc	U24HL135691	24,724	-
Cardiovascular Diseases Research	93.837	Indiana University	1R01HL15921601A1	6,300	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	5U01HL09681211	34,852	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	5U01HL09681212	36,724	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center	5R01HL06777317	109,742	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL12333606	10,900	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	1U24HL138660	13,727	-
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837	National Marrow Donor Program	4U10HL06929416	(2,188)	-
Cardiovascular Diseases Research	93.837 93.837	New England Research Institutes New England Research Institutes	5U24HL13569105 5U24HL13569106	3,311 2,854	-
Cardiovascular Diseases Research	93.837	New York University	5024HL13509100 5R01HL04509530	2,054 105,361	-
Cardiovascular Diseases Research	93.837	New York University	5R01HL04509531	238,279	_
Cardiovascular Diseases Research	93.837	Ohio State University	5R01HL12885705	(6,187)	_
Cardiovascular Diseases Research	93.837	Ohio State University	5R01HL14858104	22,593	-
Cardiovascular Diseases Research	93.837	Rector & Visitors Of The University Of Virginia	5P01HL12084009	735,961	-
Cardiovascular Diseases Research	93.837	Regents Of The University Of Michigan	4UH3HL15913402	2,852	-
Cardiovascular Diseases Research	93.837	RTI International	OT3HL14779801	(6,876)	-
Cardiovascular Diseases Research	93.837	Saint Louis University	1R01HL160553-01A1	41,833	-
Cardiovascular Diseases Research	93.837	Saint Louis University	R56HL165199	51,959	-
Cardiovascular Diseases Research	93.837	State University Of New York	5U01HL13155205	4,640	-
Cardiovascular Diseases Research	93.837	Trustees Of The University Of Pennsylvania	5R01HL13490505	31,208	-
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837	Trustees Of The University Of Pennsylvania UNandUP, LLC (UN&UP)	5R34HL14692703	8,575	-
Cardiovascular Diseases Research	93.837 93.837	University Of Alabama Birmingham	1R43HL158306-01A1 2R01HL12033807A1	17,837 24,879	-
Cardiovascular Diseases Research	93.837 93.837	University Of Alabama Birmingham University Of Alabama Birmingham	5R01HL12033807A1 5R01HL148462	24,879 39,555	-
Cardiovascular Diseases Research	93.837	University Of Alabama Birmingham	5R01HL14914503	39,555 245	-
Cardiovascular Diseases Research	93.837	University Of Alabama Birmingham	5U01HL12033806	(9)	_
Cardiovascular Diseases Research	93.837	University Of California Davis	3UH3HL14180004S1	(14,019)	_
Cardiovascular Diseases Research	93.837	University Of California Davis	5UH3HL1418002	131,935	-
Cardiovascular Diseases Research	93.837	University of California, San Francisco	5R25HL12614607	3,143	-
Cardiovascular Diseases Research	93.837	University Of North Carolina Chapel Hill	1R34HL15894701	153	-
Cardiovascular Diseases Research		1 1 0 00 1 0 11 01 1 1 11			
	93.837	University Of North Carolina Chapel Hill	5R01HL15725502	48,882	
Cardiovascular Diseases Research	93.837	University of Pennsylvania School of Medicine	5R01HL14827203	64,899	-
Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837 93.837	University of Pennsylvania School of Medicine University of Pittsburgh Medical Center	5R01HL14827203 7R01HL15946102	64,899 132,410	- - -
Cardiovascular Diseases Research	93.837	University of Pennsylvania School of Medicine	5R01HL14827203	64,899	- - -

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
Cardiovascular Diseases Research	93.837	University of Washington	1R01HL16182901	257,565	-
Cardiovascular Diseases Research	93.837	University of Washington	5P01HL15132803	364,216	-
Cardiovascular Diseases Research	93.837	University of Washington	5R01HL16182902	207,076	-
Cardiovascular Diseases Research	93.837	Yale University	5U01HL12551105	(3,834)	-
Lung Diseases Research	93.838			8,598,307	423,902
Lung Diseases Research	93.838	Children's Hospital Of Philadelphia (The)	5R01HL14805403	4,207	-
COVID19-Lung Diseases Research	93.838	Cincinnati Children's Hospital Medical Center	5U01HL13474503	38,867	-
Lung Diseases Research Lung Diseases Research	93.838 93.838	Cornell University Fred Hutchinson Cancer Center	1UG3HL15494401A1 5UH3HL14701104	7,461	-
Lung Diseases Research	93.838	Fred Hutchinson Cancer Center Fred Hutchinson Cancer Center	6UH3HL14701103	5,777 9,805	
Lung Diseases Research	93.838	Northwestern University	5P01HL15499802	46,038	_
Lung Diseases Research	93.838	NuPeak Therapeutics Inc	1R41HL14952301	(4,381)	_
Lung Diseases Research	93.838	Rector & Visitors Of The University Of Virginia	R01HL157407	58,276	-
Lung Diseases Research	93.838	Regents Of The University Of Michigan	5R01HL14726104	50,417	-
Lung Diseases Research	93.838	The Brigham And Women's Hospital Inc	5U01HL14600203	1,156	-
Lung Diseases Research	93.838	The Brigham And Women's Hospital Inc	5U01HL14600204	88,533	-
Lung Diseases Research	93.838	The Regents of the University of California	OT2HL16184701	157,068	-
COVID19-Lung Diseases Research	93.838	Trustees Of Columbia University In the City Of New York	RTI22312021757166178	5,412	-
Lung Diseases Research	93.838	Trustees Of The University Of Pennsylvania	5U01HL14885703	4,571	-
Lung Diseases Research	93.838	Trustees Of The University Of Pennsylvania	5U01HL14885704	94,285	-
Lung Diseases Research	93.838	University Of Arizona	5U01HL13004505	427,701	19,858
Lung Diseases Research	93.838	University Of Arizona	5U01HL13004506	31,812	-
Lung Diseases Research	93.838	University Of Arizona	R25-HL126140	17,148	-
Lung Diseases Research	93.838	University of Colorado Denver	5P01HL15296103	19,053	-
Lung Diseases Research	93.838	University Of North Carolina Chapel Hill	5U24HL13899805	8,095	-
Lung Diseases Research Lung Diseases Research	93.838	University Of North Carolina Chapel Hill University Of North Carolina Chapel Hill	5U24HL13899806	203,819	-
	93.838		5U54HL09645818	23,860	-
Lung Diseases Research Lung Diseases Research	93.838	University Of North Carolina Chapel Hill University of Pittsburgh	5U54HL09645819	64,215	-
Lung Diseases Research	93.838 93.838	University of Pittsburgh University of Washington	5R01HL14824704 1R03HL16025101A1	5,382	-
Lung Diseases Research	93.838	Wayne State University	5R01HL14824704	24,244 43,389	-
Lung Diseases Research	93.838	Weill Medical College of Cornell University	4R33 HL15301102	56,648	-
Blood Diseases and Resources Research	93.839	Well Medical conege of cornel chiversity	4K33 HL1530H02	9,732,929	600,293
Blood Diseases and Resources Research	93.839	Caeli Vascular, LLC	2R42HL15096302A1	146,070	000,293
Blood Diseases and Resources Research	93.839	Emory University	5UG3HL14856002	24,705	_
Blood Diseases and Resources Research	93.839	Emory University	5UG3HL14856003	86,544	_
Blood Diseases and Resources Research	93.839	Medical College Of Wisconsin	1U01HL15985001	20,778	_
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL13866002	44	_
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	R01HL131731	27,144	-
Blood Diseases and Resources Research	93.839	Nationwide Children's Hospital	1R01HL157208-01A1	75	-
Blood Diseases and Resources Research	93.839	New York University	1UG3HL15579801A1	31,980	-
Blood Diseases and Resources Research	93.839	Rutgers The State University Of NJ	5U01HL13381705	2,942	-
Blood Diseases and Resources Research	93.839	St. Jude Children's Research Hospital	5U01HL13399604	(9,839)	-
Blood Diseases and Resources Research	93.839	University Of Alabama Birmingham	1UG3HL157401-01A1	28,917	-
Blood Diseases and Resources Research	93.839	University Of Alabama Birmingham	5R01HL13389604	8,690	-
Blood Diseases and Resources Research	93.839	University of Colorado Denver	4R33HL14179403	51,993	-
Blood Diseases and Resources Research	93.839	University Of Maryland	7UH3HL14319205	36,547	-
Blood Diseases and Resources Research	93.839	University Of Pittsburgh	5UH3HL14319203	5,676	-
Blood Diseases and Resources Research	93.839	Versiti Wisconsin Inc	5P01HL14445704	395,739	-
Blood Diseases and Resources Research	93.839	Versiti Wisconsin Inc	5R01HL06883515	14,387	
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders COVID19-Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	New York University	oT2HL156812	3,858,792	1,073,255
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840 93.840	Universidad Peruana Cayetano Heredia	5UGHL150812 5UGHL15237102	243,191 56,736	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Universidad Peruana Cayetano Heredia	5UGHL1523/102 5UGHL15237103	50,/30 88,972	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	University of Abuja	4UG3HL1523/103	15,718	
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	University of Abuja	5UG3HL15238102	13,682	_
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Vanderbilt University	1OT2HL15681201	268,780	_
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	value on versity	10121111,001201	14,904,198	930,376
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Biorestorative Therapies Inc	1R41AR0793401	54,891	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Boston University	5R01AR07442804	4,120	_
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Of Philadelphia (The)	1R01AR07982201	3,905	_
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Cleveland Clinic Lerner College of Medicine	3R01AR07542204S1	6,404	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Hebrew Rehabilitation Center	5R01AR07534602	24,639	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Icahn School Of Medicine At Mount Sinai	5R01AR07700703	34,259	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Indiana University	5R01AR07647702	3,875	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR07601304	16,471	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northeast Ohio Medical University	5R01AR07776202	39,000	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents Of The University Of Michigan	5R01AR07936702	87,903	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Rush University Medical Center Obligated Group	5P30AR079206-02	9,947	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Steadman Philippon Research Institute	1R21AR07907501A1	97,618	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Brigham And Women's Hospital Inc	5R01AR05555712	22,172	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Brigham And Women's Hospital Inc	U01AR070498	7,660	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees Of Columbia University In the City Of New York	5R01AR06294709	250,310	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Akron	1R21AR07474301A1	6,321	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of California Irvine	1R01AR078340	82,228	-

	Assistance	n m Indi	Pass-through Entity	Total	Passed to Sub-
Cluster Title/Federal Grantor/Program Title	Listing Number		Identification Number	Expenditures	Recipients
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of Pittsburgh	5R01AR07614604	67,893	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of Southern California	5R01AR07221205	55,336	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of Texas Southwestern Medical Center	1R01AR078311-01A1	44,913	-
Arthritis, Musculoskeletal and Skin Diseases Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.846	Vanderbilt University	5R01AR06084608	163,731	- - 077 040
COVID19-Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	Albert Einstein College of Medicine	5P30DK020541-47S1	47,086,892 64,997	5,077,349 32,485
Diabetes, Digestre, and Kidney Diseases Extramural Research	93.847	Ann & Robert H. Lurie Children's Hospital of Chicago	1U01DK12799501	24,309	32,403
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Ann & Robert H. Lurie Children's Hospital of Chicago	5U01DK12799502	15,596	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5U24DK11525504	43,896	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Beckman Research Institute of the City of Hope	U24DK104162-09	131,238	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Bioio, LLC	1R42DK12165201A1	75,560	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	1R01DK11672301A1	15,324	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	2U01DK094157-12	118,888	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars Sinai Medical Center	5U01DK06241320	6,195	-
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	Children's Hospital Of Philadelphia (The) Cleveland Clinic Lerner College of Medicine	5R01DK09783007 5R01DK12279002	28,625	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK122/9002 5U01DK09824609	372,530 2,588	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK09824009 5U01DK09824610	20,815	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Georgia Institute Of Technology	R01DK133702	91,019	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Lung Therapeutics	1R43DK12401001A1	20	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	McGill University	5R01DK11073703	3,684	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Hospital	5U01DK10086609	2,615	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northern California Institute For Research And Education	5R01DK12564602	41,721	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	2R01DK09221709	67,454	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5P30DK11485704	29,263	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5R01DK12574902	185	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Oregon Health & Science University	5R01DK11549505	246	-
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	PlatformSTL PlatformSTL	1R41DK135161-01 5R42DK12025303	61,436 216,649	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	Rector & Visitors Of The University Of Virginia	5R42DK12025303 5R01DK11186104	1,496	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Rutgers The State University Of NJ	1R01DK113288501	44,594	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Saint Louis University	1R01DK13453101	5,746	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Saint Louis University	2R56DK11040606A1	5,919	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Sanford Research	1R01DK131020-01A1	5,168	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Senseion Therapeutics, Inc.	2R44DK12159802A1	304,542	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Senseion, LLC (Inactive)	1R44DK12660001	275,536	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	State University Of New York	5R01DK11448503	8,323	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Board Of Trustees Of The Leland Stanford Junior University	5U01DK13006002	7,593	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Board Of Trustees Of The Leland Stanford Junior University	Uo1DK130060	975	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Brigham And Women's Hospital Inc	1U24DK135157-01	58,874	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Children's Mercy Hospital	5U01DK06614320	3,112	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Medical University Of South Carolina (Inactive)	5U01DK10483306	7,898	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Regents of the University of California	128178108 (S9002561)	394	-
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Alabama Birmingham University Of Alabama Birmingham	5P30DK07933715 5R01DK12749702	45,270	-
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	University of California, San Francisco	5R01DK12749702 5R01DK11598703	274,321 48,103	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Francisco	5R01DK11598703 5R01DK12279704	28,732	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Chicago	5P01DK05678818	(1,021)	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Chicago	5U54DK11861203	26,746	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Chicago	5U54DK11861204	167,782	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Colorado Denver	1U01DK12919101	2,481	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Florida	7R01DK114485-05	40,979	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	3U01DK10833407S1	248	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	3U01DK108334-08S1	2,268	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	5R01DK11875204	13,797	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa University of Kansas Medical Center	5U01DK10833407	35,723	-
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	University of Kansas Medical Center University of Kansas Medical Center	1R01DK134737-01 1R56DK12923401	10,403	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Maryland, Baltimore	5U24DK126110-03	1,337 49,181	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Washington	5U2CDK11488605	49,161	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Wisconsin	1R01DK11814501A1	55,472	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	1R01DK1101430111	10,476	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Wake Forest University	5R01DK12887102	42,215	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Weill Medical College of Cornell University	5R01DK12581702	20,107	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	XN Biotechnologies, LLC	1R41DK12913801A1	59,205	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			47,582,439	5,956,123
COVID19-Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			55,518	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Albany Research Institute	7U01NS10891603	160,009	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	1R21NS12721101A1	11,199	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center	5R01NS118146604	9,826	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853		7R01NS118146603	8,634	-
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	Boston University California Institute Of Technology	5U01NS09333407 1U01NS12656201	25,680 187,501	-
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	California Institute Of Technology California Institute Of Technology	5R01NS10227903	46,800	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's National Health System	5R01NS1022/903 5R01NS11229405	29,152	-
and the state of t	73.033		0	29,132	

	Assistance		Pass-through Entity	Total	Passed to Sub-
Cluster Title/Federal Grantor/Program Title	Listing Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cleveland Clinic Foundation	U01NS116776	75,875	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Collaborations Pharmaceuticals Inc	1R43NS10707901	85	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Duke University	5R01NS11158803	32,795	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	5U54NS11602510	390,669	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	FreeFlow Medical Device LLC	2R42NS10370402A1	256,007	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Harvard University	U2CNS132415	8,872	-
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Hugo W Moser Research Institute at Kennedy Krieger Inc Hugo W Moser Research Institute at Kennedy Krieger Inc	5K12NS09848205 5K12NS09848206	280	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	5K12NS09848206 5R01NS10629202	121,546 476	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	Johns Hopkins University	5U01NS11167803	141,167	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS117609-03	39,824	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5RO1NS11102904	23,320	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U01NS09676704	625	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U01NS11400102	10,567	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS095388	(14,587)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS120901	4,549	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Minnetronix	5R44NS11024703	1,585	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion Inc	2R42NS11364201	95,471	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion Inc	2R42NS11518402	178,634	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion Inc	5R42NS11518403	123,832	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	National Institute for Health Research	1K08NS11788801A1	(11,593)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	New York University	5R01NS11069602	7,105	-
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University Northwestern University	5R01NS12586302 5U01NS11385102	51,981	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	Northwestern University Nous Imaging Inc	1R44NS12952101	4,976 61,127	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Ohio State University	Ro1NS094292	20,217	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Ohio State University	1R01NS12368701	12,055	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Oregon Health & Science University	1015486_WUSTL	220,989	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Phoenix Nest Inc	2U44NS08906105	58,422	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rector & Visitors Of The University Of Virginia	1R01NS12567701A1	54,907	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rector & Visitors Of The University Of Virginia	5R01NS09911804	56,683	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents Of The University Of Colorado	1U01NS11431201A1	48,013	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Research Foundation of the City University of New York	5R01NS11801202	20,804	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rhaeos Inc	1U44NS12155501	124,603	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rutgers The State University Of NJ	5U24NS09591407	217,412	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Saint Louis University	5R01NS11428904	19,345	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Jude Children's Research Hospital	5R01NS12111403	222,730	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Louis College of Pharmacy	1R34NS126036-01	248,553	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Louis College of Pharmacy	5R01NS12307002	48,200	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of Columbia University In the City Of New York	1R01NS11082601A1	4,230	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of Columbia University In the City Of New York	5R01NS11082602	2,116	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of Columbia University In the City Of New York	5R01NS11082603	50,817	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of Columbia University In the City Of New York	5R211NS11306303	47,354	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University Of Pennsylvania	582577	255,452	-
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University Of Pennsylvania Trustees Of The University Of Pennsylvania	5R01NS11586902S1	34,682	-
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University Of Pennsylvania Trustees Of The University Of Pennsylvania	5U19NS11045602 5U19NS11045603	1,652 506	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	Trustees Of The University Of Pennsylvania	5U19NS11045604	636,093	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	UNandUP, LLC (UN&UP)	1R44NS12260401	95,031	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Alabama Birmingham	5U01NS09259504	31,011	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Arizona	R01NS127108	19,757	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	1U01NS12083601	155,176	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	1U54NS12398501	349,908	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5R01NS058721-13	88,125	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5R01NS111166-03	26,009	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Chicago	5R01NS11626202	135,282	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS09904301A1	32,883	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS10228901A1	30,405	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS10665501A1	106,272	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS11072801	3,788	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS11077201	20,547	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS117450-01A1	34,010	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	5U01NS09586902	20,770	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	5U01NS10651302	32,675	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Connecticut	7U01NS10069903	39,921	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Connecticut	5R01NS10263306	96,371	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Florida University Of Florida	5U01NS11956202	3,012	-
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	University of Illinois Chicago	5U01NS11956203 1R01NS127403-01A1	1,280 65,145	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	University of Illinois Chicago University Of Miami	1U24NS12085801	05,145 140,484	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.053	University Of North Carolina Chapel Hill	5R01NS12223002	134,701	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Southern California	5R01NS03446724	229,990	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas Health Science Center at Houston	1R61NS11332901	2,769	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Utah	10050533-10	2,709	_
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Utah	5U01NS10748604	120,239	-
- v		:		., 0)	

	Assistance		Pass-through Entity	Total	Passed to Sub-
Cluster Title/Federal Grantor/Program Title	Listing Number		Identification Number	Expenditures	Recipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Washington	1U01NS128537-01	98,868	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Washington	5R01NS09161807	59,773	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Vanderbilt University	5UH3NS116218-03	25,519	-
Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Wayne State University Weill Medical College of Cornell University	5R01NS09457004	5,540	-
Extramurar Research Frograms in the Neurosciences and Neurological Disorders Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.853 93.855	Welli Medical College of Cornell Olliversity	5R01NS11199703	115,060 65,336,506	9,897,607
COVID19-Allergy and Infectious Diseases Research	93.855			738,518	65,213
Allergy and Infectious Diseases Research	93.855	Albert Einstein College of Medicine	5R01AI15819402	261,704	-
Allergy and Infectious Diseases Research	93.855	Baylor College of Medicine	2R01AI03295630	(228)	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute At Virginia Mason	1U19AI67891-01	149,114	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute At Virginia Mason	2UM1AI10956509	136,048	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute At Virginia Mason	5U19AI6789102	106,978	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute At Virginia Mason	5UM1AI10956509	15,752	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute At Virginia Mason	5UM1AI10956510	43,603	-
Allergy and Infectious Diseases Research	93.855	Big Eye Diagnostics	1R43AI17245901	21,818	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855 93.855	Boston Children's Hospital (Inactive) Boston University	1R56AI16301301 1R21AI15623601	6,205 33,638	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855	Case Western Reserve University	5R21AI13989802	29,625	
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855	Cedars Sinai Medical Center	1R01AI17042401	30,529	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation	5U01AI12661406	132,159	_
Allergy and Infectious Diseases Research	93.855	Children's Hospital Of Philadelphia (The)	1R01AI17151401	104,229	-
Allergy and Infectious Diseases Research	93.855	Cleveland Clinic Lerner College of Medicine	R01AI127774	(8,405)	-
Allergy and Infectious Diseases Research	93.855	Drexel University	5U19AI12891005	9,407	-
Allergy and Infectious Diseases Research	93.855	Duke University	U01AI163065	71,187	-
Allergy and Infectious Diseases Research	93.855	Duke University	1R01AI13903201	(5,804)	-
Allergy and Infectious Diseases Research	93.855	Duke University	1U01AI16309901	81,233	-
Allergy and Infectious Diseases Research	93.855	Duke University	5R01AI14582804	381,755	-
Allergy and Infectious Diseases Research	93.855	Emory University	3U19AI11048308S4	192,559	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855 93.855	Emory University Emory University	5R01AI12520201 5U01AI15074703	396 188,022	-
Allergy and Infectious Diseases Research	93.855	Emory University	A540588	100,022	
COVID19-Allergy and Infectious Diseases Research	93.855	Family Health International	UM1AI068619	356,942	-
Allergy and Infectious Diseases Research	93.855	Fimbrion Therapeutics Inc	1R43AI17255901A1	9,055	_
Allergy and Infectious Diseases Research	93.855	Fimbrion Therapeutics Inc	5R43AI14983302	(214)	-
Allergy and Infectious Diseases Research	93.855	Fimbrion Therapeutics Inc	5R44AI14983304	322,399	-
Allergy and Infectious Diseases Research	93.855	Forward Defense LLC	1R41AI16713701A1	129,945	-
Allergy and Infectious Diseases Research	93.855	Fox Chase Cancer Center	1R56AI15096501A1	96,103	-
Allergy and Infectious Diseases Research	93.855	Icahn School Of Medicine At Mount Sinai	1R01AI168178-01	171,017	-
Allergy and Infectious Diseases Research	93.855	Icahn School Of Medicine At Mount Sinai	5R01AI16817802	57,399	-
Allergy and Infectious Diseases Research	93.855	Icahn School Of Medicine At Mount Sinai	5R21AI16704703	18,279	-
Allergy and Infections Diseases Research	93.855	Icahn School Of Medicine At Mount Sinai	HHSN272201400008C	125,091	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855	Integrated BioTherapeutics Inc Johns Hopkins University	1R41AI5274501A1 2P30AI09418911	32,509	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855 93.855	La Jolla Institute for Immunology	5U19AI14279003	45,450 4,156	
Allergy and Infectious Diseases Research	93.855	La Jolla Institute for Immunology	5U19AI14279004	547,812	_
Allergy and Infectious Diseases Research	93.855	Los Angeles Biomedical Research Institute	5U01AI11640004	1,874	_
Allergy and Infectious Diseases Research	93.855	Los Angeles Biomedical Research Institute	5U01AI11640005	50,843	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	1U01AI16308601	49,874	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI16308602	120,418	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	5U01AI12661006	17,138	-
Allergy and Infectious Diseases Research	93.855	MicroBiotix Inc	1R41AI16510201A1	90,667	-
Allergy and Infectious Diseases Research	93.855	Mississippi State University	5R21AI14221003	(38)	-
Allergy and Infectious Diseases Research	93.855	Northwestern University	5P30AI11794307 Revised	63,164	-
Allergy and Infectious Diseases Research	93.855	Oregon Health & Science University	5R01AI13218605	178,392	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855 93.855	Oregon Health & Science University Regents Of The University Of Colorado	5R21AI14465802 5R01AII4143602	5,396 288,274	-
Allergy and Infectious Diseases Research		Regents Of The University Of Colorado Regents Of The University Of Michigan			-
Allergy and Infectious Diseases Research	93.855 93.855	Regents Of The University Of Michigan	1U54AI17066001 2R01AI13467805	196,873 122,264	-
Allergy and Infectious Diseases Research	93.855	Regents Of The University Of Michigan	5U54AI17066002	59,752	-
Allergy and Infectious Diseases Research	93.855	Saint Louis University	5R01AI13019002	75,817	_
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	U19AI171443	336,975	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	1U19 AI171443-01	184,861	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5U19AI17144302	29,452	-
Allergy and Infectious Diseases Research	93.855	St. Jude Children's Research Hospital	3U01AI14461603S1	213,471	-
Allergy and Infectious Diseases Research	93.855	St. Jude Children's Research Hospital	5U01AI14461604	165,584	-
Allergy and Infectious Diseases Research	93.855	Temple University	1UM1AI164568	466,528	-
Allergy and Infectious Diseases Research	93.855	Texas Tech University System	1R15AI15674601A1	11,716	-
Allergy and Infectious Diseases Research	93.855	The Board Of Trustees Of The Leland Stanford Junior University	3U01AI13595003S1	(39,585)	-
Allergy and Infectious Diseases Research	93.855	The Board Of Trustees Of The Leland Stanford Junior University	5U19AI16448408	419	-
Allergy and Infectious Diseases Research	93.855	The Jackson Laboratory	5U19AI14273303	123,282	-
Allergy and Infectious Diseases Research	93.855	The Jackson Laboratory	5U19AI14273305	40,316	-
Allergy and Infectious Diseases Research	93.855	The Regents of the University of California	1R01AI16989201A1	161,482	-
Allergy and Infectious Diseases Research	93.855	The Regents of the University of California	5R01AI11463508	35,072	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855 93.855	The Regents of the University of California Thomas Jefferson University	7R21AI15204902	37,237	-
metal and meetals Disease Research	93.000	Thomas seneratin curversity	5R01AI16584002	31,235	-

	Assistance		Pass-through Entity	Total	Passed to Sub-
Cluster Title/Federal Grantor/Program Title	Listing Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Allergy and Infectious Diseases Research	93.855	Trustees Of The University Of Pennsylvania	5R01AI14053905	248,352	-
Allergy and Infectious Diseases Research	93.855	University Of Alabama Birmingham	5U19AI142759	214,941	_
Allergy and Infectious Diseases Research	93.855	University Of Alabama Birmingham	5U54AI15022503	41,940	-
Allergy and Infectious Diseases Research	93.855	University Of Alabama Birmingham	5U54AI15022504	6,265	-
Allergy and Infectious Diseases Research	93.855	University Of Arizona	2R01AI12994506	3,698	-
Allergy and Infectious Diseases Research	93.855	University Of Arizona	5R01AI12994505	4,969	-
Allergy and Infectious Diseases Research	93.855	University of Calgary	5R01AI16532702	58,437	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855	University Of California Los Angeles University of California, San Francisco	UM1AI068636	214,170	-
Allergy and Infectious Diseases Research	93.855 93.855	University of California, San Francisco University of California, San Francisco	1P01AI15539301A1 5U54AI08297314	472,095 11,978	-
Allergy and Infectious Diseases Research	93.855	University of California, Santa Barbara	5054A10629/314 5R21AI16448302	72,361	
Allergy and Infectious Diseases Research	93.855	University of Camorina, Santa Barbara University Of Florida	5R01AI14147805	49,859	_
Allergy and Infectious Diseases Research	93.855	University Of Kentucky	3R01AI140758-04S1	116,939	_
Allergy and Infectious Diseases Research	93.855	University Of Kentucky	5R01AI14075805	315,811	-
Allergy and Infectious Diseases Research	93.855	University Of Louisville	1R01AI3967101A1	22,219	-
Allergy and Infectious Diseases Research	93.855	University Of Pittsburgh	1R21AI163606-02	75,281	-
Allergy and Infectious Diseases Research	93.855	University Of Pittsburgh	1R56AI17192001	144,573	-
Allergy and Infectious Diseases Research	93.855	University Of Pittsburgh	5R01AI14266205	58,419	-
Allergy and Infectious Diseases Research	93.855	University Of Pittsburgh	1R01AI16551901	8,885	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh School of Medicine	5R01AI15021403	71,860	-
Allergy and Infectious Diseases Research	93.855	University Of Texas	5R21AI12950502	(263)	-
Allergy and Infectious Diseases Research	93.855	University of Texas Medical Branch	5R01AI14635302	157,876	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern	5U19AI14278404	544,156	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern	5U19AI14278405	319,846	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5R01AI1459603	1,628	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855	University of Washington University Of Wisconsin	5R01AI1459604 1UM1AI16004001	189,215 394,604	-
Allergy and Infectious Diseases Research	93.855 93.855	University Of Wisconsin	1UM1AI16004001	360,940	-
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	5P01AI13213205	63,723	
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	5R01AI13251904	31,179	
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	5R01AI13251904 5R01AI13864704	41,352	_
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	5R01AI15067803	139,371	_
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	5R01AI15313004	85,451	_
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	5UM1AI148452-03	1,190	_
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	5UM1AI14845204	31,344	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	3UM1AI14845202S4	8	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	1R01AI17215601	191,855	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	3UM1AI14845203S3	325,764	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	501AI12782805	22,265	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI14845203S3	484,854	-
COVID19-Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	UM1AI068619	(3,304)	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	UM1AI068619	111,174	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	UM1AI069439	757,630	-
Allergy and Infectious Diseases Research	93.855	VaxNewMo, LLC	1R41AI16707801	128,296	-
Allergy and Infectious Diseases Research COVID19-Allergy and Infectious Diseases Research	93.855	VaxNewMo, LLC Washington State University	1R42AI165116	176,194	-
Allergy and Infectious Diseases Research	93.855	Weill Medical College of Cornell University	5U01AI5179903	56,627	-
Allergy and Infectious Diseases Research	93.855 93.855	Weill Medical College of Cornell University	5U01AI095608-13 5U01AI095608-13	4,523 12,313	-
Biomedical Research and Research Training	93.859	Well Medical College of Collien Chiversity	5001A1095000-13	34,055,397	615,058
Biomedical Research and Research Training	93.859	BioRankings LLC	2R44GM13148702	(11,233)	-
Biomedical Research and Research Training	93.859	Cornell University	1R25GM14207001	38,637	_
Biomedical Research and Research Training	93.859	Florida International University	5R01GM13424703	42,011	-
Biomedical Research and Research Training	93.859	GenNext Technologies Inc	1R43GM14235101	(1,104)	-
Biomedical Research and Research Training	93.859	Icahn School Of Medicine At Mount Sinai	7R01GM14344002	27,078	-
Biomedical Research and Research Training	93.859	Protein Metrics Inc	2R42GM12113302	(8,069)	-
Biomedical Research and Research Training	93.859	Regents Of The University Of Michigan	5U54AI15047010	97,154	-
Biomedical Research and Research Training	93.859	Saint Louis University	1R01GM134081	294,021	-
Biomedical Research and Research Training	93.859	The Jackson Laboratory	5R01GM12573604	5,607	-
Biomedical Research and Research Training	93.859	University Of Alabama Birmingham	5R25GM13051704	68,533	-
Biomedical Research and Research Training	93.859	University Of Florida	5R01GM13904603	203,646	-
Biomedical Research and Research Training	93.859	University Of Pittsburgh University Of Texas	5R01GM10861807	8,006	-
Biomedical Research and Research Training Biomedical Research and Research Training	93.859	University Of Texas Vanderbilt University	5R01GM11423706 5R01GM11661607	145,304	-
Child Health and Human Development Extramural Research	93.859 93.865	variacioni University	2K01QM1100100/	55,042 20,333,480	4,641,232
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD07281509	20,333,480	4,041,232
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD0/281509 5R01HD09113005	34,369 37,874	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD09113005 5R01HD09244405	3/,6/4 134,728	-
Child Health and Human Development Extramural Research	93.865	Childrens Hospital Los Angeles	7R21HD08678403	3,002	_
Child Health and Human Development Extramural Research	93.865	Children's Hospital Of Philadelphia (The)	1R01HD109963	178,283	-
Child Health and Human Development Extramural Research	93.865	Indiana University	7R01HD08600704	37,562	-
Child Health and Human Development Extramural Research	93.865	Johns Hopkins University	5R01HD09769204	18,835	-
Child Health and Human Development Extramural Research	93.865	Medical College Of Wisconsin	R01HD104607	13,608	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	5R01HD09134704	20,209	-
Child Health and Human Development Extramural Research	93.865	Neurolutions	4R44HD105579-02	136,859	-
Child Health and Human Development Extramural Research	93.865	Northwestern University	5K12HD07394510	39,719	-

Cluster Title/Federal Grantor/Program Title	Assistance	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
					Recipients
Child Health and Human Development Extramural Research	93.865	Oklahoma State University	2R01HD07457911	10,302	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	5U24HD10098203	4,560	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	5U54HD10098203	33,387	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	5U54HD10098204	101,075	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	7R01HD07864107	(7,760)	-
Child Health and Human Development Extramural Research	93.865	Rector & Visitors Of The University Of Virginia	5R01HD07207107	132,170	-
Child Health and Human Development Extramural Research	93.865	Regents Of The University Of Colorado	5R01HD09799004	106,611	-
Child Health and Human Development Extramural Research	93.865	Seattle Children's Hospital, Research and Foundation	5R01HD102239-03	27,607	-
Child Health and Human Development Extramural Research	93.865	St. Louis College of Pharmacy	4R33HD09974804	82,984	-
Child Health and Human Development Extramural Research	93.865	The Children's Hospital Of Philadelphia (Inactive)	5R01HD10152803	24,813	-
Child Health and Human Development Extramural Research	93.865	Trustees Of Columbia University In the City Of New York	5R01HD09100305	21,105	-
Child Health and Human Development Extramural Research	93.865	University at Buffalo	1RO101HD104814-01A1	21,643	-
Child Health and Human Development Extramural Research	93.865	University of California, San Francisco	5R01HD09241904	(1,248)	-
Child Health and Human Development Extramural Research	93.865	University Of Chicago	5R01HD09984702	119,290	-
Child Health and Human Development Extramural Research	93.865	University of Massachusetts Medical School	7R01HD09506005	36,086	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina Chapel Hill	2R01HD05574116	306,057	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina Chapel Hill	5R01HD05574115	46,929	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina Chapel Hill	5R01HD10390202	53,226	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh School of Medicine	1R25HD109110-01	13,471	-
Child Health and Human Development Extramural Research	93.865	University Of Texas	7U01HD07738406	20,208	-
Child Health and Human Development Extramural Research	93.865	University of Texas Southwestern	Po1HDo84387	385,283	98,796
Child Health and Human Development Extramural Research	93.865	University of Washington	5R01HD10157802	141,906	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	1R01HD10585501A1	17,279	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	1R01HD10821001	41,064	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	5001861-WU-CARTER	33,813	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	5R01HD10585502	12,015	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	R01HD105855-01A1	23,859	-
Child Health and Human Development Extramural Research	93.865	Yale University	5R01HD106326-02	3,279	_
Aging Research	93.866	· ·		112,015,423	24,254,448
COVID19-Aging Research	93.866			1,552,273	675,372
Aging Research	93.866	Active Life Scientific	1R22AG07103401	209,641	- 70,07
Aging Research	93.866	Baylor College of Medicine	5P01AG06660603	396,974	_
Aging Research	93.866	Baylor University	5R01AG06529002	66,587	_
Aging Research	93.866	Cancer and Aging Research Group	5R33AG05920604	(939)	_
Aging Research	93.866	Duke University	1U19AG065188-01	12,546	_
Aging Research	93.866	Duke University	5R24AG05435506	(1,822)	_
Aging Research	93.866	Duke University	5R33AG07045502	3,008	
Aging Research	93.866	George Washington University	1U19AG078558-01	186,931	
Aging Research	93.866	Harvard School of Public Health	5R01AG06093503	5,063	
Aging Research	93.866	Hebrew Rehabilitation Center	5R33AG07174402	1.029	
Aging Research	93.866	Indiana University	5U01AG05719504	436,320	
Aging Research	93.866	Indiana University	5U01AG05/19504 5U01AG05/19505		-
Aging Research	93.866	Johns Hopkins University	1RF1AG05/19505	66,520	-
Aging Research	93.866	Johns Hopkins University	5R01AG04028209	121,537 281,125	-
					-
Aging Research	93.866	Mayo Clinic	1U19AG06970101	809,550	-
Aging Research	93.866	Mayo Clinic Mayo Clinic	5K23AG06402904	18,789	-
Aging Research	93.866		5U19AG06391103	474,161	-
Aging Research	93.866	Mayo Clinic	5U19AG06970102	840,144	-
Aging Research	93.866	Mayo Clinic	WUB-284424/PO #68089509	(603)	-
Aging Research	93.866	Mayo Clinic	WUB-284424/PO #69081362	63,109	-
Aging Research	93.866	Medical College Of Wisconsin	1R01AG07773201	231,801	-
Aging Research	93.866	Northern California Institute For Research And Education	2U19AG02490416	274,667	-
Aging Research	93.866	Northern California Institute For Research And Education	U19AG024904	150,471	-
Aging Research	93.866	Northwestern University	3R01AG06857902S1	141,350	-
Aging Research	93.866	Northwestern University	5U2CA0604260404S1	22,261	-
Aging Research	93.866	Ohio State University	R01AG056919A	88,452	-
Aging Research	93.866	Parabon Nanolabs Inc	2R44AG06207202A1	2,294	-
Aging Research	93.866	Pelagos Pharmaceuticals Inc	1R41AG07977801A1	849	-
Aging Research	93.866	Pennsylvania State University	5U2CAG06040805	46,582	-
Aging Research	93.866	Rector & Visitors Of The University Of Virginia	5R01AG06704802	206,013	-
Aging Research	93.866	Regenerative Research Foundation	1U1AG07246401	130	-
Aging Research	93.866	Regenerative Research Foundation	1U1AG07246402	425,769	-
Aging Research	93.866	Regenerative Research Foundation	5R01AG05629305	320,756	-
Aging Research	93.866	Regents Of The University Of California	1RF1AG05900901	288,742	-
Aging Research	93.866	Regents Of The University Of Michigan	1R01AG074887-02	25,159	-
Aging Research	93.866	Regents Of The University Of Michigan	5R01AG06258203	76	-
Aging Research	93.866	Regents Of The University Of Michigan	5U24AG06518204	1,291	-
Aging Research	93.866	Ridgeline Therapeutics LLC	1U44AG07410701	3,449	-
Aging Research	93.866	Rutgers The State University Of NJ	5R01AG05555605	19,021	-
Aging Research	93.866	Saint Louis University	5R01AG05871404	(1,709)	_
Aging Research	93.866	The Board Of Trustees Of The Leland Stanford Junior University	5R37AG00881632	11,529	_
Aging Research	93.866	The Brigham And Women's Hospital Inc	1RF1AG07956901	14,853	_
Aging Research	93.866	The Jackson Laboratory	5R01AG07401202	329,930	20,435
Aging Research	93.866	The Regents of the University of California	5R01AG0/401202 5R01AG06114603	11,331	20,400
Aging Research	93.866	Trustees Of Columbia University In the City Of New York	5U24UA05627005	23,832	•
guig seconder	93.000	Tracess of Columbia Oniversity III the City Of New 101K	50240A0502/005	23,632	-

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
Aging Research	93.866	Trustees Of Columbia University In the City Of New York	5U24UA05627007	11,140	
Aging Research	93.866	Trustees Of The University Of Pennsylvania	1R01AG06857701	51,661	_
Aging Research	93.866	Trustees Of The University Of Pennsylvania	1R01AG06993601A1	129,572	_
Aging Research	93.866	Trustees Of The University Of Pennsylvania	5P01AG03186215	41,689	_
Aging Research	93.866	Trustees Of The University Of Pennsylvania	5R01AG05443503	186,225	-
Aging Research	93.866	Tufts University	5R01AG07171702	188,901	-
Aging Research	93.866	University Of Alabama Birmingham	1R01AG06839501A1	22,388	-
Aging Research	93.866	University Of California Berkeley	1R01AG07895801	98,927	-
Aging Research	93.866	University Of California Los Angeles	5R01AG05436605	6,274	-
Aging Research	93.866	University of California, San Francisco	5P30AG06242202	8,180	-
Aging Research	93.866	University of California, San Francisco	5R01AG03879110	50,156	-
Aging Research	93.866	University of California, San Francisco	5R01AG06235905	422,011	-
Aging Research	93.866	University of California, San Francisco	5U24AG07269902	10,989	-
Aging Research	93.866	University of California, San Francisco	U19AG024904-16	53,080	-
Aging Research	93.866	University Of Chicago	1R01AG07654101	442	-
Aging Research	93.866	University of Connecticut	5R01AG0688603	2,641	-
Aging Research	93.866	University of Illinois Chicago	1R01AG07654101	138,398	-
Aging Research	93.866	University Of Kentucky	5R01AG03865109	37,279	-
Aging Research	93.866	University of Melbourne	5R01AG05867604	797,783	-
Aging Research	93.866	University Of Miami	5R01AG06461404	419,239	-
Aging Research	93.866	University Of North Texas Health Science Center	1U19AG078109-01	76,010	-
Aging Research	93.866	University Of Pittsburgh	1R01AG06487701A1	472,738	-
Aging Research	93.866	University Of Pittsburgh	1U19AG06805401	242,165	-
Aging Research	93.866	University Of Pittsburgh	5R01AG06049905	216,458	-
Aging Research	93.866	University Of Pittsburgh	5U19AG06805403	845,883	-
Aging Research	93.866	University of Pittsburgh School of Medicine	1R01AG07326701	449,524	-
Aging Research	93.866	University of Rhode Island	1R01AG079241-01	115,097	-
Aging Research	93.866	University Of Rochester	5P01AG04720009	49,335	-
Aging Research	93.866	University Of Southern California	136854271	7,469	-
Aging Research	93.866	University Of Southern California	1R01AG05379801A1	27,587	-
Aging Research	93.866	University Of Southern California	1R01AG06368901	107,947	-
Aging Research	93.866	University Of Southern California	1R56AG05872601A1	8,774	-
Aging Research	93.866	University Of Southern California	1R61AG06654301	13,942	-
Aging Research	93.866	University Of Southern California	2P01AG05235006	141,201	-
Aging Research	93.866	University Of Southern California	2U19AG02490413	2,432	-
Aging Research	93.866	University Of Southern California	2U19AG024904-16	8,874	-
Aging Research	93.866	University Of Southern California	5P01AG052350	177,879	-
Aging Research	93.866	University Of Southern California	5R01AG05379804	85,271	-
Aging Research	93.866	University Of Southern California	5R01AG05402902	4,808	-
Aging Research	93.866	University Of Southern California	5R61AG06654302	41,790	-
Aging Research	93.866	University Of Southern California	5U24AG05743704	126,783	-
Aging Research	93.866	University Of Texas Health Science Center At San Antonio	5R01AG05789604	2,690	-
Aging Research	93.866	University Of Texas Southwestern Medical Center	5R01AG04974905	59,896	-
Aging Research	93.866	University of Washington	1U24AG07212201	1,249	-
Aging Research	93.866	University of Washington	3U24AG07212201S1	103,155	-
Aging Research	93.866	University of Washington	5R01AG06375902	32,958	-
Aging Research	93.866	University of Washington	5U24AG07212202	20,170	-
Aging Research	93.866	University Of Wisconsin	5R01AG07002802	279,572	-
Aging Research	93.866	University Of Wisconsin	5R01AG07088302	43,114	-
Aging Research	93.866	Vanderbilt University Medical Center	1R01AG07343901	143,778	-
Aging Research	93.866	Vanderbilt University Medical Center	5U24AG07485502	194,332	-
Aging Research	93.866	Vivid Genomics Inc	1R43AG07610601A1	114,070	-
Aging Research	93.866	Wake Forest University	1R01AG078153-01	52,888	-
Aging Research	93.866	Yale University	5R01AG06591703	211,540	-
Aging Research	93.866	Yale University	5R33AG05892605	22,472	-
Aging Research	93.866	Yale University	5R61AG06982202	141,302	-
Vision Research	93.867			8,525,020	395,720
Vision Research	93.867	Johns Hopkins University	5UG1EY02809103	32,317	-
Vision Research	93.867	Legacy Emanuel Hospital & Health Center	5R34EY03142702	5,443	-
Vision Research	93.867	The Regents of the University of California	5R21EY03112502	(35)	-
Vision Research	93.867	University of Massachusetts Medical School	5R01EY02860203	76,467	-
Vision Research	93.867	West Virginia University	5UG1EY03165402	2,844	-
Vision Research	93.867	West Virginia University	5UG1EY03165403	16,300	-
Medical Library Assistance	93.879			385,640	40,985
Medical Library Assistance	93.879	University of California, San Francisco	1R01LM01377802	141,764	-
Global Health Research and Research Training	93.989			1,402,092	637,396
Global Health Research and Research Training	93.989	Centre for Infectious Disease Research in Zambia	1D71TW01183702	4,087	=
Global Health Research and Research Training	93.989	Northwestern University	1D43TW011976-01	8,197	-
Global Health Research and Research Training	93.989	University Of Texas Health Science Center At San Antonio	9D43TW01179306A1	3,707	-
COVID19-National Center for Advancing Translational Sciences (NCATS)	93.RD	Regenstrief Institute	75N95021D00028	60,229	-
			GS-OOF-01OCA/HHSN261201700003B/		
National Cancer Institute (NCI)	93.RD	ICF Incorporated, LLC	75N91022F00002/TO9	129,522	-
	ga.RD	Leidos Biomedical Research	75N91019D00024	307.525	
COVID19-National Cancer Institute (NCI) National Cancer Institute (NCI)	93.RD 93.RD	Leidos Biomedical Research Leidos Biomedical Research	75N91019D00024 75N91019D00024	307,525 10,257	-

Material (uncer familitie (PCI)	ıres	Passed to Sub- Recipients
National Canor Institute NCD 1,000 Remetal Research 750/monotonomy 1,000 Remetal Remetal 750/monotonomy 1,000 Remetal Remetal 750/monotonomy 1,000 Remetal Remetal 1,000 Remetal Re		Recipients
School Career Institute (NCI) School Career Institute (NCI	1,312	-
National Cancer Institute (NCT)	47,570	-
National Cancer Institute (NCI) 93.8D Medical Science & Computing 73,9860cc00006/73980cca0fe 73,9860cc0006/73980cca0fe 73	36,877) 64,624)	-
National Cancer Institute (NCI) Space Sp	3,007	-
National Content of Reference Institute (PCI) OUTD-Schelder (Deep reference Institute (PCI) OUTD-Schelder (DEEP) (PCI)	1,200	-
COVED-19-Astional Concer Institute (NCT) Constitute (NCT) Consti	30,690	-
National Hoof, Lang and Blood Institute (NILI) National Hoof, Lang and Blood Institute (NILI) National Hoof, Lang and Blood Institute (NILI) National Hoof, Lang and Blood Institute (NILII) National Institute of Alberg and Infections Diseases (NIAID) National Institute of NIAID of Alberg and Infections Diseases (NIAID) National Institute of NIAID of Alberg and Infections Diseases (NIAID) National		
National Flants, Lang and Blood estatines (NHLBH) 9,31D Johns Flophian Linkwesty 4,48596 1888-1869-1860-1860-1860-1860-1860-1860-1860-1860	61,018	32,017
National Institute of Allery and Infection Institute (NILIII)	76,814	-
COVID-19-Astional Heart. Lang and Blood Institute (CHLBI) CRUPT- Astional Heart. Lang and Blood Institute (CHLBI) CRUPT- ASTIONAL CRUPT-	(760) 17,069	-
COVID-9-Sational Heart. Lung and Blood Institute (NILIER)	(6,800)	-
COUTION-9 Astional Institute of Allery and Infoctions Descase (NAID) County Co		-
National Institute of Allergy and Infectious Diseases (NAID)	16,456	-
COVID-9-Astional Institute of Allerys and Infections Diseases (NIAID)	(1,967)	
National Institute of Allery and Infections Diseases (NIAID)	47,649	656,050
National Institute of Allergy and Infections Diseases (NIAID) 93 ND 1.0	7,451	-
National Institute of Allerg and Infections Diseases (NIADI) National Institute of Diseases (NIADI) National Institute of Allerg and Infections Diseases (NIADI) National Institute of Health (NIH) National Institute of Health (NIH	23,792	-
National Institute of Allerg and Infections Diseases (NIAID)	23,422	-
National Institute of Allergy and Infections Diseases (NIAID) National Institute on Divid Allery and Infections Diseases (NIAID) National Institute on Divid Allery and Infections Diseases (NIAID) National Institute on Divid Allery and Infections Diseases (NIAID) National Institute on Divid Allery and Infections Diseases (NIAID) National Institute on Divid Allery and Infections Diseases (NIAID) National Institute on Divid Allery and Infections Diseases (NIAID) National Institute on Divid Allery and Infections Diseases (NIAID) National Institute on Divid Allery and Infections Diseases (NIAID) National Institute of Health (NIII) National Institute on Divid Allery and Infections Diseases (NIAID) National Institute on Health (NIII) National In	80,470	-
National Institute of Allery and Infectious Diseases (NIAID)	44,748	-
National Institute of Alleryg and Infections Diseases (NAIDD) 93, RD 1, winersity of Alabama, Birmingham HISN272201600007C 1, winersity of Habama HISN272	6,085	-
National Institute of Allery and Infections Diseases (NAID) Sa, D. University of Alabama, Birningham HISN7-2201600007C	25,451	-
National Institute of Allery and Infectious Diseases (NIAID)	12,486)	-
National Institute on Drug Abase (NIDA) 93, RD University of Montana HHSN27210400050C National Institute on Drug Abase (NIDA) 93, RD Rutgers University 78,96029D009 HHSN271201800023I HHSN271201800023I HHSN271201800023I HHSN271201800023I HHSN271201800023I HHSN271201800023I HHSN2712018000023I HHSN271201800023I HHSN2712018000023I HHSN27120180000023I HHSN27120180000023I HHSN2712018000023I HHSN27120180000023I HHSN2712018000023I H	3,965	-
National Institute on Drug Abase (NIDA) 93,RD Rugers University 78,05029,Doo.00 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,01000.003 11,8572,0100.003	24,600	-
National Institute on Drug Abuse (NIDA) 93,RD Rugers University HISNS2712008000231	22,456	-
National Institutes of Heatth (NIH)	92,322	-
National Institutes of Health (NIH)	82,737	-
COVID-9-Astional Institutes of Health (NIH)	1,922	-
National Institutes of Health (NH) 33,RD 11 (International 31,RD 12 (International 31,RD	3,234	-
National Institutes of Health (NIFI) 93,RD University of California, Los Angeles Unknown 1111 1	(4,122)	-
National Institutes of Health (NIH)	25,977	-
National Institutes of Health (NIH) 93,RD Vivent HISNS 0120160000071 93,RD Vivent HISNS 012016000071 93,RD Vivent HISNS 012016000071 93,RD Vivent HISNS 012016000071 93,RD Vivent MISNS 01201600071	32,093	-
National Institutes of Health (NIH)	(146)	-
Deligy Research and Evaluation Grants Office on Women's Health Services Administration Projects of Regional and National Significance Projects of Regional and National Significance Projects of Regional and National Significance TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL AERONAUTICS AND SPACE ADMINSTRATION National Aeronautics and Space Administration Science	09,130	-
Policy Research and Evaluation Grants Office on Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health COVID19-Advancing System Improvements for Key Issues in Women's Health CovID19-Advancing System Improvements for Key Issues in Women's Health CovID19-Advancing System Improvements for Key Issues in Women's Health CovID19-Advancing System Improvements for Key Issues Institute System Institute of Messouri, St. Louis System Issues Iss	21,780	-
Office on Women's Health COVIDIO-Advancing System Improvements for Key Issues in Women's Health Substance Abuse and Mental Health Services Administration Projects of Regional and National Significance NATIONAL AERONAUTICS AND SPACE ADMINISTRATION NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Science Scienc		
COVIDO-Advancing System Improvements for Key Issues in Women's Health Substance Administration Projects of Regional and National Significance Projects of Regional Andional Significance Projects of Regional Andional Significance Projects of Regional Antional Significance Projects of Regional Antional Significance Projects of Real-IT AID Missouri, St. Louis Projects of Missouri, St. Louis	4,876	-
Substance Abuse and Mental Health Service's Administration		
Projects of Regional and National Significance	37,928	-
Projects of Regional and National Significance 93.243 University of Missouri, St. Louis SM085050		
NATIONAL AERONAUTICS AND SPACE ADMINSTRATION	07,536	-
NATIONAL AERONAUTICS AND SPACE ADMINSTRATION String	19,123	-
Science 43.001 California Institute of Technology 80NSSC18K0223 California Institute of Technology 80NSSC18K0223 California Institute of Technology 80NSSC2K05640 California Institute of Technology 80NSSC2K105 California Institution 80NSSC2K105 California Institution Rondon Institution California Institution Californ	99,958	86,984,389
Science 43.001		
Science 43.001 California Institute of Technology 80NSSC18K0223 Science 43.001 California Institute of Technology 80NSSC20K0540 Science 43.001 Colorado School of Mines 80NSSC22K1055 Science 43.001 Planetary Science Institute 80NSSC17K0543 Science 43.001 Princeton University 80NSSC1K1057 Science 43.001 Rensselaer Polytechn Institute 80NSSC19M0069 Science 43.001 Smithsonian Institution GO0-21046A Science 43.001 Smithsonian Institution GO122033B Science 43.001 Smithsonian Institution GO122091X Science 43.001 Smithsonian Institution NAS8-03060 Science 43.001 Smithsonian Institution NAS8-0306 Science 43.001 Smithsonian Institution NAS8-0306 Science 43.001 Smithsonian Institution NAS8-0306 Science 43.001 University of Chicago 80NSSC2LM016		
Science 43.001 California Institute of Technology 80NSSC18K0223 Science 43.001 California Institute of Technology 80NSSC2K0540 Science 43.001 Colorado School of Mines 80NSSC2EM105 Science 43.001 Planetary Science Institute 80NSSC17K0343 Science 43.001 Princeton University 80NSSC1K1957 Science 43.001 Rensselaer Polytechnic Institute 80NSSC1K1957 Science 43.001 Smithsonian Institution GO0-21046A Science 43.001 Smithsonian Institution GO1-2003B Science 43.001 Smithsonian Institution GO122091X Science 43.001 Smithsonian Institution MAS8-03060 Science 43.001 Smithsonian		
Science 43,001 California Institute of Technology 80NSSC2x605040 Science 43,001 Yolordo School of Mines 80NSSC2x1105 Science 43,001 Planetary Science Institute 80NSSC2x1057 Science 43,001 Princeton University 80NSSC2x1057 Science 43,001 Rensselaer Polytechnic Institute 80NSSC1x1057 Science 43,001 Smithsonian Institution GO0-21046A Science 43,001 Smithsonian Institution GO122033B Science 43,001 Smithsonian Institution GO122091X Science 43,001 Smithsonian Institution NAS8-0360 Science 43,001 Smithsonian Institution MAS8-0360 Science 43,001 Smithsonian Institution MSSC1x105 Science 43,001 Smithsonian Institution MSSC3x2x100 Science 43,001 Smithsonian Institution MSSC3x2x10x10x1 Science 43,001 University of Chicago 80NSSC1x10x10x1	17,005	1,317,017
Science 43.001 Colorado School of Mines 80NSSC2xK105 Science 43.001 Planetary Science Institute 80NSSC17K0343 Science 43.001 Princeton University 80NSSC1K1957 Science 43.001 Rensselaer Polytechnic Institute 80NSSC19M0669 Science 43.001 Smithsonian Institution G0-21046A Science 43.001 Smithsonian Institution G0122031B Science 43.001 Smithsonian Institution G0122091X Science 43.001 Smithsonian Institution NAS8-0360 Science 43.001 Smithsonian Institution MAS8-0306 Science 43.001 University of Chicago 80NSSC2MD16	14,514	-
Science 43,001 Planetary Science Institute 80NSSC17K0343 Science 43,001 Princeton University 80NSSC17K037 Science 43,001 Rensselaer Polytechnic Institute 80NSSC19M0069 Science 43,001 Smithsonian Institution GO0-21046A Science 43,001 Smithsonian Institution GO1-2204B Science 43,001 Smithsonian Institution GO122091X Science 43,001 Smithsonian Institution NAS8-03060 Science 43,001 Smithsonian Institution MAS8-03060 Science 43,001 Smithsonian Institution MSSC1M016 Science 43,001 University of Chicago 80NSSC1M016	15,985	-
Science 43.001 Princeton University 80NSSC21K1957 Science 43.001 Renesslear Polytehin Institute 80NSSC19M069 Science 43.001 Smithsonian Institution GO0-21046A Science 43.001 Smithsonian Institution G0122033B Science 43.001 Smithsonian Institution G0122091X Science 43.001 Smithsonian Institution NAS8-0360 Science 43.001 Smithsonian Institution TM1-2203X Science 43.001 University of Chicago 80NSSC1M016	23,082	-
Science 43.001 Rensselaer Polytechnic Institute 80NSSC19M0069 Science 43.001 Smithsonian Institution GO0-21046A Science 43.001 Smithsonian Institution GO122033B Science 43.001 Smithsonian Institution GO122031X Science 43.001 Smithsonian Institution NAS8-03060 Science 43.001 Smithsonian Institution TM1-22003X Science 43.001 University of Chicago 80NSSC1M0116	(10)	-
Science 43.001 Smithsonian Institution GO0-21046A Science 43.001 Smithsonian Institution GO12203B Science 43.001 Smithsonian Institution GO12209IX Science 43.001 Smithsonian Institution NAS8-0360 Science 43.001 Smithsonian Institution TM1-22003X Science 43.001 University of Chicago 80NSSC2IM016	11,637	-
Science 43.001 Smithsonian Institution GO122033B Science 43.001 Smithsonian Institution GO122091X Science 43.001 Smithsonian Institution NAS8-0360 Science 43.001 Smithsonian Institution TM1-22003X Science 43.001 University of Chicago 80NSSC21M0116	68,669	-
Science 43.001 Smithsonian Institution GO122091X Science 43.001 Smithsonian Institution NAS8-03060 Science 43.001 Smithsonian Institution TM1-22003X Science 43.001 University of Chicago 80NSSC21M0116	25,766	-
Science 43.001 Smithsonian Institution NAS8-0306 Science 43.001 Smithsonian Institution TM1-2203X Science 43.001 University of Chicago 80NSS21M016	23,311	-
Science43.001Smithsonian InstitutionTM1-22003XScience43.001University of Chicago80NSSC21M0116	18,179	-
Science 43.001 University of Chicago 80NSSC21M0116	22,330	-
	23,668	-
China de Cilia de Cil	46,145	-
Science 43.001 University of Illinois at Urbana-Champaign 80NSSC21K1986	6,835	-
Science 43.001 University of New Mexico 80NSSC19K0958	99,766	-
Space Operations 43.007	(2,246)	-
Education 43.008 Missouri University of Science and Technology NNX15AK03H	(2,754)	-
Education 43.008 University of Missouri System 80NSSC20M0100	32,818	-
Space Technology 43.012	73,332	111,451
NASA 43.RD Arizona State University NNG07EK00C	59,500	-
NASA 43,RD Jet Propulsion Laboratory Unknown	27,219	-
NASA 43.RD Jet Propulsion Laboratory 1549716	33,332)	-
NASA 43,RD Jet Propulsion Laboratory NM0710630	32,573	_
NASA 43,RD Jet Propulsion Laboratory NMO710805	45,970	_
NASA 43,RD Johns Hopkins University 1277793	(1,668)	_
43.RD Southwest Research Institute	53,267	_
NASA 43,RD Southwest Research Institute NNN12AA01C	1,551	_

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
NASA	43.RD	University of Texas Austin	80NSSC20K0361	37,823	-
TOTAL NATIONAL AERONAUTICS AND SPACE ADMINSTRATION	10	•	•	10,850,935	1,428,468
NATIONAL SCIENCE FOUNDATION					
National Science Foundation					
National Science Foundation	47.RD			179,321	-
Engineering Grants	47.041			3,492,056	647,369
COVID19-Engineering Grants Engineering Grants	47.041 47.041	Renerva LLC	Unknown	(2,792) 100,659	_
Engineering Grants	47.041	Trustees of Clark University	2144977	36,423	-
Engineering Grants	47.041	Trustees Of The University Of Pennsylvania	CMMI-1548571	978,445	-
Engineering Grants	47.041	University of Central Florida	1908167	19,260	-
Engineering Grants Engineering Grants	47.041 47.041	University of Illinois at Urbana-Champaign Washington State University	1900277 2124088	97,943 9,698	-
Engineering Grants Mathematic and Physical Sciences	47.049	washington state University	2124088	3,883,474	65,058
Mathematic and Physical Sciences	47.049	Barnard College	1828168	16,500	-
Mathematic and Physical Sciences	47.049	Harvard University	2127882	211,039	-
Mathematic and Physical Sciences	47.049	University of Minnesota	CHE1906135	18,663	-
Geosciences Computer and Information Science and Engineering	47.050			1,478,441 3,698,478	68,593
Computer and Information Science and Engineering	47.070 47.070	Colorado School of Mines	2118201	150,999	- 00,393
Computer and Information Science and Engineering	47.070	George Mason University	Unknown	37,880	-
Computer and Information Science and Engineering	47.070	University of California, Berkely	1640899	(2,092)	-
Computer and Information Science and Engineering	47.070	University of Illinois, Urbana-Champaign	2103680	49,287	-
Computer and Information Science and Engineering Computer and Information Science and Engineering	47.070	University of Utah University of Utah	1622741 2002158	9,257	-
Computer and Information Science and Engineering Computer and Information Science and Engineering	47.070 47.070	University of Utah	2002158 CNS182688	294,280 71,144	-
Computer and Information Science and Engineering	47.070	University of Utah	CNS1827940	81,442	-
Computer and Information Science and Engineering	47.070	Virginia Polytech Institute	CNS-1837519	47,507	-
Computer and Information Science and Engineering	47.070	West Virginia University	IIS-2114644	153,194	-
Biological Sciences Biological Sciences	47.074	American University	10101	3,870,074	371,183
Biological Sciences	47.074 47.074	Baylor College of Medicine	1948181 2131806	23,053 31,240	
Biological Sciences	47.074	Baylor College of Medicine	DBI-2021795	159,247	_
Biological Sciences	47.074	Carnigie Institution of Washington	DBI-2213983	34,526	-
Biological Sciences	47.074	Michigan State University	2243230	9,798	-
Biological Sciences Biological Sciences	47.074	University of Wisconsin, Madison University of Wisconsin, Madison	1818040 1840687	(1,653)	-
Social, Behavioral, and Economic Sciences	47.074 47.075	University of Wisconsin, Madison	104000/	72,044 1,451,805	137,708
Social, Behavioral, and Economic Sciences	47.075	Boston University	SES2120115	22,349	-
Social, Behavioral, and Economic Sciences	47.075	Georgia State University	1740201	4,760	-
Education and Human Resources	47.076			1,722,529	51,306
Education and Human Resources Education and Human Resources	47.076	Harris-Stowe State University Jackson State University	1619639	1,841	-
Education and Human Resources	47.076 47.076	University of Alabama	2000135 1915544	7,635 51,767	-
Polar Programs	47.078	on conjunt	-7-3344	45,773	_
Office of International Science and Engineering	47.079			51,790	3,055
Office of International Science and Engineering	47.079	CFDF Global	OISE9531011	(1,000)	-
Office of International Science and Engineering COVID19-Office of Integrative Activities	47.079	University of Wisconsin	Unknown	16,907	-
NSF Technology, Innovation, and Partnerships	47.083 47.084		OISE20665901	169,274 94,180	
TOTAL NATIONAL SCIENCE FOUNDATION	47.004		010120005901	22,948,445	1,344,272
AGENCY FOR INTERNATIONAL DEVELOPMENT					
Agency for International Development Agency for International Development Foreign Assistance for Programs Overseas	98.001	Mississippi State University	7200AA18CA00030	94,618	
Agency for International Development Foreign Assistance for Programs Overseas Agency for International Development Foreign Assistance for Programs Overseas	98.001	National Academy of Sciences	7200AA18CA00030 AID263A1500002	94,618 61,587	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	University Of Georgia	7200AA18CA00003	147,001	47,410
Agency for International Development Foreign Assistance for Programs Overseas	98.001	University of London	Unknown	42,730	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Washington State University	7200AA21CA00033	376,378	-
Agency for International Development Agency for International Development	98.RD 98.RD	Mississippi State University Mississippi State University	19390031245502E	35,433	-
DEPARTMENT OF AGRICULTURE	98.KD	mississippi state University	7200AA18CA00030	21,469	-
National Institute of Food and Agriculture					
Biotechnology Risk Assessment Research	10.219			71,428	-
Agriculture and Food Research Initiative (AFRI)	10.310	TT 1 1 00TT 11		274,530	166,858
Agriculture and Food Research Initiative (AFRI) Agriculture and Food Research Initiative (AFRI)	10.310	University Of Hawaii Washington State University	2020-67022-31146	22,554	-
Agriculture and Food Research Initiative (AFRI) DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT	10.310	washington state university	2022-68016-37113	62,344	-
Department of Housing and Urban Development Department of Housing and Urban Development					
Homeland Security Research, Development, Testing, Evaluation and Demonstration of Technologies Related to Countering Weapons of					
Mass Destruction	97.077	City of St. Louis	19DNFRV000010201	(27,787)	-
DEPARTMENT OF JUSTICE Crime Victim Assistance/Discretionary Grants	16 =0=			222.	22.27
Public Safety Partnership and Community Policing Grants	16.582 16.710	Center for Naval Analyses	15JCOPS21GK02399SPPS	202,919 106,283	39,139
y	10./10		1,0001.0210102.3990110	100,203	

Cluster Title/Federal Grantor/Program Title	Assistance	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
DEPARTMENT OF STATE	Listing Number	1 ass 1 mough Entity	identification Number	Expenditures	Recipients
International Programs to Combat Human Trafficking	19.019			239,212	51,463
International Programs to Combat Human Trafficking	19.019	University Of Georgia	SSJTIP22CA0029	27,490	-
Public Diplomacy Programs	19.040			8,989	-
Overseas Refugee Assistance Programs for Strategic Global Priorities	19.522	I-b Hbi H-iib-	mm.i.a. a	242,379	-
Bureau of Near Eastern Affairs	19.600	Johns Hopkins University	SMEAAC21CA3040	50,938	-
DEPARTMENT OF TRANSPORTATION Federal Highway Administration					
National Highway Traffic Safety Administration	20.RD	Wake Forest University	693JJ922F00202N	12,119	_
National Highway Traffic Safety Administration	20.RD	Wake Forest University	DTNH2217D00070	1,292	-
DEPARTMENT OF VETERANS AFFAIRS		•			
Department of Veterans Affairs	64.RD	TI'S CONTROL IN COLUMN		86,748	-
Department of Veterans Affairs ENVIRONMENTAL PROTECTION AGENCY	64.RD	University Of North Carolina Chapel Hill	36C24120D0021	30,375	-
Office of Research and Development					
Science to Achieve Results (STAR) Research Program	66.509			357,494	-
NATIONAL ENDOWMENT FOR THE HUMANITIES					
Promotion of the Arts Grants to Organizations and Individuals	45.024			13,295	-
Promotion of the Humanities - Fellowships and Stipends	45.160	California State University, Long Beach	RZ-287012-22	110,181 2,383	-
Promotion of the Humanities Research Total Research & Development Cluster	45.161	Camorina State University, Long Beach	KZ-28/012-22	772,417,998	94,230,859
-					741-J=1=37
Other Sponsored Programs DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Administration for Strategic Preparedness & Response					
Strengthening Emergency Care Delivery in the United States Healthcare System through Health Information and Promotion	93.078			50,262	-
Centers for Disease Control					
Centers for Disease Control and Prevention Centers for Disease Control and Prevention	93.U01			42,598	-
Centers for Disease Control and Prevention Centers for Disease Control and Prevention	93.U02 93.U03			125,511 59,270	-
Centers for Disease Control and Prevention	93.U03			584,694	-
Colorectal Cancer Screening Program	93.800	University of Missouri	5NU58DP0067650300	14,012	
		•			-
HIV Prevention Activities Non-Governmental Organization Based	93.939	Vivent Health	1NU62PS924648-01-00	75,403	-
HIV Prevention Activities_Health Department Based	93.940	Missouri Deparment of Health and Human Services	DH200047810	91,111	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	11107110010	73,826	-
HIV Prevention Activities_Health Department Based HIV Prevention Activities Health Department Based	93.940	City of St. Louis Department of Health City of St. Louis Department of Health	11667114011 1166-7114720	125,649	-
TOTAL HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	93.940	City of St. Louis Department of Hearth	1100-/114/20	164,489 455,075	
Assistance Programs for Chronic Disease Prevention and Control	93.945	Missouri Department Of Health & Senior Services	DH200048448	36,038	
-	93-943	Missouri Department of Hearth & Sellior Services	D11200040440	30,030	
Food and Drug Administration					
Food and Drug Administration Food and Drug Administration	93.U09 93.U10	American College of Medical Toxicology Inc	75F40122D00028	54,885	-
rood and Drug Administration	93.010	American Conege of Medical Toxicology Inc	/5F40122D00028	15,443	-
Health Resources and Services Administration		77 N. D 1 7	** 1		
Health Resources and Services Administration	93.U14	Health Research Inc	Unknown	19,595	-
Trans-NIH Research Support	93.110	University of Texas Health Science Center At San Antonio	H30MC24051-11-00	22,012	=
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	5U03MC22684-11-00	142,789	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	6U03MC22684-11-01	16,414	-
TOTAL EMERGENCY MEDICAL SERVICES FOR CHILDREN				159,203	-
Sickle Cell Treatment Demonstration Program	93.365			835,017	459,643
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	21-83	(1,365)	
HIV Emergency Relief Project Grants HIV Emergency Relief Project Grants	93.914 93.914	City of St. Louis Department of Health	2H89HA000332400	(1,563)	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	2H89HA000332800	76,322	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	H98HA000332900	93,016	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	22-56	23,650	-
HIV Emergency Relief Project Grants HIV Emergency Relief Project Grants	93.914 93.914	City of St. Louis Department of Health City of St. Louis Department of Health	22-65 23-46	342,076 37,997	-
HIV Emergency Relief Project Grants HIV Emergency Relief Project Grants	93.914 93.914	City of St. Louis Department of Health	23-46 23-44	37,997 308,020	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	23-47	7,013	-
TOTAL HIV EMERGENCY RELIEF PROJECT GRANTS		-		885,166	-
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	05780063H-4-1	123,761	_
HIV Care Formula Grants HIV Care Formula Grants HIV Care Formula Grants	93.917 93.917	Missouri Department of Health and Senior Services Missouri Department of Health and Senior Services Missouri Department of Health and Senior Services	05780063H-4-1 X07HA00030 DH200048389	123,761 88,230	- 22,167

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
HIV Care Formula Grants TOTAL HIV CARE FORMULA GRANTS	93.917	Missouri Department of Health and Senior Services	DH230051646	395,767 1,245,528	66,466 88,633
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918			545,964	49,834
Special Projects of National Significance	93.928			243,067	11,663
Office of Assistant Secretary for Health Family Planning Services	00.015	Missouri Family Health Council	FPHPA006455	5 9aa	
Family Planning Services	93.217 93.217	Missouri Family Health Council	FPHPA006561	5,893 265,230	-
TOTAL FAMILY PLANNING SERVICES				271,123	-
Office of the Secretary of Health and Human Services COVID19-Biomedical Advanced Research and Development Authority (BARDA)	93.U16	Duke University	HHS0100201400002I	147,458	-
Substance Abuse and Mental Health Services Administration Substance Abuse and Mental Health Services Projects of Regional and National Significance					
Substance Abuse and Mental Health Services_Projects of Regional and National Significance Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243 93.243	Vision for Children at Risk	VCRSTLPL	133,146 93,416	-
${\tt TOTALSUBSTANCEABUSEANDMENTALHEALTHSERVICESPROJECTSOFREGIONALANDNATIONALSIGNIFICANCE}$				226,562	-
Congressional Directives	93.493	BJC health System	1H79FG00082201	31,920	-
State Targeted Response to the Opiod Crisis Grants	93.788	University of Missouri, St. Loius	AOC21380034	44,661	-
State Targeted Response to the Opiod Crisis Grants TOTAL STATE TARGETED RESPONSE TO THE OPIOD CRISIS GRANTS	93.788	University of Missouri, St. Loius	1H79TI085748-01	103,453 148,114	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				6,293,920	609,773
OTHER FEDERAL PROGRAMS					
AGENCY FOR INTERNATIONAL DEVELOPMENT Food for Peace Development Assistance Program (DAP)	98.007	Catholic Relief Services	720BHA21RFA00002	334,222	_
DEPARTMENT OF DEFENSE U.S. Army Medical Command	90.007	Catholic Rener Services	/20DIM2IKI100002	334,222	
Military Medical Research and Development	12.U01	Synedgen Inc	(MTEC)-2021-476	7,385	-
Military Medical Research and Development TOTAL DEPARTMENT OF DEFENSE	12.U01	University of Pittsburgh School of Medicine	W81XWJ16D0024W81XWH18F04	22,859 30,244	
DEPARTMENT OF ENERGY DEPARTMENT OF Energy	81.U01			64,534	_
DEPARTMENT OF JUSTICE	01.001			04,334	
Office of Juvenile Justice and Delinquency Prevention Second Chance Act Reentry Initiative	16.812	Soulfisher Minsitry	15BJA-22-GG-01773-SCAX	6,593	
Second Chance Act Reentry Initiative TOTAL DEPARTMENT OF JUSTICE	16.812	Soulfisher Minsitry	15RBJA-22-GG-04605-SCAX	13,885	-
DEPARTMENT OF LABOR					
WIOA Adult Program DEPARTMENT OF STATE	17.258	Missouri Department Of Higher Education	AA-34778-20-55-A-29	29,090	-
AEECA/ESF PD Programs DEPARTMENT OF THE TREASURY	19.900	American Councils for International Education	SUZ80021CA3148	24,698	-
Internal Revenue Service	0				
Low Income Taxpayer Clinics NATIONAL ARCHIVES AND RECORDS ADMINISTRATION	21.008			123,715	-
National Archives and Records Administration National Archives and Records Administration	89.Uo1	National Film Preservation Foundation	FED20027	3,563	-
NATIONAL ENDOWMENT FOR THE ARTS Promotion of the Arts Grants to Organizations and Individuals	45.024		,	8,863	_
NATIONAL ENDOWMENT FOR THE HUMANITIES Promotion of the Humanities Division of Preservation and Access	45.149			12,650	
Total Other Sponsored Programs from Other Federal Agencies	45.149			652,057	
Total Other Sponsored Programs				6,945,977	609,773
Student Financial Assitance Cluster DEPARTMENT OF EDUCATION					
Federal Supplemental Educational Opportunity Grant	84.007			1,315,106	-
Federal Work-Study Program Federal Pell Grant Program	84.033 84.063			1,629,589 6,868,579	-
Teacher Education Assistance for College and Higher Education Grants	84.379			124,476	-
Education Stabilization Fund Federal Direct Student Loans	84.425			14,737	-
New Loans Issued during 2023	84.268			65,526,726	-
Federal Perkins Loans Outstanding Loans as of July 1, 2022	84.038			10,482,949	_
New Loans Issued during 2023	84.038				=
Administrative Cost Allowance	84.038			-	-

	Assistance		Pass-through Entity	Total	Passed to Sub-
Cluster Title/Federal Grantor/Program Title	Listing Number	Pass Through Entity	Identification Number	Expenditures	Recipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Health Professions Student Loans including Primary Care Loans/Loans for Disadvantaged Students					
Outstanding Loans as of July 1, 2022	93.342			-	-
New Loans Issued during 2023	93.342			-	-
Administrative Cost Allowance	93.342				-
Total Student Financial Assistance Cluster				85,962,162	
Highway Safety Cluster					
DEPARTMENT OF TRANSPORTATION					
Police Traffic Services	20.600	Missouri Dept of Transportation	22-DL-02-002	4,278	_
Police Traffic Services	20.600	Missouri Dept of Transportation	23DL02001	90,378	-
Total Highway Safety Cluster			*	94,656	-
TRIO Cluster					
DEPARTMENT OF EDUCATION					
TRIO - Student Support Services	84.042			313,435	-
Medicaid Cluster					
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Medical Assistance Program	93.778	Missouri Department of Health and Senior Services	ER100160099	173,705	_
Total Federal Award Expenditures	93.770			\$ 865,907,933	\$ 94,840,632

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the expenditures of Washington University (the "university") under programs of the Federal Government for the year ended June 30, 2023. Expenditures of direct awards to the university are reported in total by program. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulation Part 200, *Uniform Administrative Requirements, Cost Principals, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the basic financial statements. The university includes the amounts in the Schedule in net assets without donor restrictions of the university's Consolidated Statement of Activities for the year ended June 30, 2023.

The Schedule is prepared on the accrual basis of accounting. Assistance Listing and pass-through numbers are provided when available. Negative amounts presented as expenditures represent subsequent period adjustments, transfers, or vendor credits. Expenditures are recognized following the cost accounting principles contained in the Uniform Guidance wherein certain types of expenditures are not allowable or are limited to reimbursement. Moreover, expenditures include a portion of costs associated with general university activities which are allocated to awards under negotiated formulas commonly referred to as facilities and administrative cost rates.

Federal Awards

For purposes of the Schedule, federal awards include all grants, contracts and similar agreements entered into directly by the university with agencies and departments of the Federal Government and all awards received as a subrecipient from nonfederal organizations pursuant to federal grants, contracts and similar agreements.


2. Facilities and Administrative Costs

The university recovers facilities and administrative costs under federal financial assistance programs using predetermined rates ranging from 26.0% to 57.5%. The university does not use the 10% de minimis cost rate but instead has negotiated the rates above with the Department of Health and Human Services through June 30, 2023.

3. Federal Student Loan Programs

The following schedule includes the Student Financial Aid (SFA) loan balances outstanding as of June 30, 2023:

	Federal Assistance	Outstanding
Student Financial Aid	Listing Number	Balances
U.S. Department of Education		
Federal Perkins Loan Program	84.038	7,026,348





Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Board of Trustees of Washington University

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Washington University and its subsidiaries (the "University"), which comprise the consolidated statement of financial position as of June 30, 2023, and the related consolidated statements of activities and of cash flows for the year then ended, including the related notes (collectively referred to as the consolidated financial statements), and have issued our report thereon dated October 6, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.



Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

Pricinahimaniclasses LLP

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

St. Louis, Missouri October 6, 2023



Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance

To the Board of Trustees of Washington University

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Washington University's (the "University") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2023. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance).Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.



Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliannce with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of
 expressing an opinion on the effectiveness of the University's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as items 2023-001. Our opinion on each major federal program is not modified with respect to this matter.



Government Auditing Standards requires the auditor to perform limited procedures on the University's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs and corrective action plan. The University's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

St. Louis, Missouri March 1, 2024

Pricinahimanicapers LLP



Washington University EIN# 43-0653611 Schedule of Findings and Questioned Costs For the Year Ended June 30, 2023

Part I - Summary of Auditor's Results

Financial Statements	
Type of auditor's report issued:	Unmodified
Internal control over financial reporting:	
Material weakness (es) identified?	Yes <u>X</u> No
Significant deficiency (ies) identified not considered to be material weaknesses?	Yes <u>X</u> None reported
Noncompliance material to financial statements noted?	Yes <u>X</u> No
Federal Awards	
Type of auditor's report issued on compliance for major programs:	Unmodified
Internal control over major programs:	
Material weakness (es) identified? Significant deficiency (ies) identified not considered to be material weaknesses? Any audit findings disclosed that are required to be	YesX No YesX None reported
reported in accordance with Uniform Guidance Section 200.516(a)?	X Yes No
Identification of Major Programs:	
Assistance Listing Number(s)	Name of Federal Program or Cluster
Various	Research and Development Cluster
93.365	Sickle Cell Treatment Demonstration Program
Dollar threshold used to distinguish between Type A and Type B programs:	\$3,000,000
Auditee qualified as low-risk auditee?	<u>X</u> Yes No

Washington University EIN# 43-0653611 Schedule of Findings and Questioned Costs For the Year Ended June 30, 2023

Part II - Financial Statement Findings

There are no financial statement findings to report.

Part III - Federal Award Findings and Questioned Cost

Finding 2023-001 Allowable costs/cost principles - Cost Transfers

Federal Agency:

Department of Health and Human Services, National Institutes of Health Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Program:

Research and Development Cluster Sickle Cell Treatment Demonstration Program

Assistance Listing #:

93.395, 93.242 93.365

Award #:

5R01CA25831102, 5R01MH11676804 2U1EMC278650800

Award Year:

7/1/2022 - 6/30/2023, 7/1/2022 - 6/30/20239/1/2021 - 8/31/2022

Pass-through Number:

Not applicable Not applicable

Criteria

The National Institute of Health's (NIH) Grants policy manual requires cost transfers to NIH grants by recipients, consortium participants, or contractors under grants that represent corrections of clerical or bookkeeping errors to be accomplished within 90 days of when the error was discovered.

The Department of Health and Human Services Grants policy manual requires permissible cost transfers to be made promptly after the error occurs but no later than 90 days following occurrence unless a longer period is approved in advance by the Grants Management Office.

The University's Cost Transfer policy requires cost transfers to be allocable, allowable, reasonable, and submitted in a timely manner.

Condition

Research and Development Cluster

We selected 25 cost transfers, which included cost transfers related to payroll and non-payroll costs, totaling \$368,956. During our testing, we noted 2 of 25 cost transfers, totaling \$24,438, that were not completed within the timeframe noted above. The cost transfers were completed 8 to 16 days late.

Washington University EIN# 43-0653611 Schedule of Findings and Questioned Costs For the Year Ended June 30, 2023

Other Major Program - Sickle Cell Treatment Demonstration Program

We selected 19 cost transfers, which included cost transfers related to payroll and non-payroll costs, totaling \$28,628. During our testing, we noted 1 of 19 cost transfers, totaling \$4,951, that was not completed within the timeframe noted above. The cost transfer was completed 55 days late.

Cause

The university has a cost transfer policy which includes a requirement for cost transfers to be made in a timely manner. However, there were certain instances where there were delays in processing cost transfers which ultimately resulted in the completion of the cost transfer process outside of the timeframe required by the regulations.

Effect

There were certain cost transfers that were processed outside of the timeframe that is allowed by the federal regulations.

Questioned Costs


There are no questioned costs associated with this finding as the costs transferred were allowable and allocable to the awards to which they were transferred.

Recommendation

We recommend management continue to educate staff on the cost transfer policy, with a specific emphasis on the importance of processing cost transfers in a timely manner.

Views of Responsible Officials

Please refer to management's views and corrective action plan.



Washington University EIN# 43-0653611 Management's Views and Corrective Action Plan For the Year Ended June 30, 2023

Washington University in St. Louis

Accountant's Finding 2023 - 001

Management concurs with the finding and is implementing the following corrective actions:


- The University's Cost Transfer for Sponsored Projects policy has been updated (completed February 2024) to include more specific language regarding the timing requirements for awards from the National Institutes of Health, the Department of Health and Human Services, and Other Sponsoring agencies (see below).
- Management will regularly send targeted communication to the Principal Investigators and the appropriate research administrators in their academic units that hold awards from the Department of Health and Human Services agencies (non-NIH) as a reminder that DHHS requires permissible cost transfers to be made promptly after the error occurs but *no later than 90 days following occurrence unless a longer period is approved in advance by the Grants Management Office.*
- Management will provide ongoing communication to the research community about the importance of adhering to cost transfer deadlines through its various communication channels, including, but not limited to, Research Administrator meetings and the Research News emails.

Update to Cost Transfer for Sponsored Projects policy:

Faculty and staff are responsible for ensuring that Cost Transfers are processed in a timely manner. Cost Transfers should be prepared and submitted within 90 days from the date of discovery (per National Institutes of Health Grants Policy Statement section 7.5). In cases when the sponsor's (federal or non-federal) terms and conditions relating to the timing of Cost Transfers are stricter than this policy, the sponsor's terms and conditions are applicable and supersede this policy. Note: The Department of Health and Human Services agencies (e.g., funding from HRSA, CDC, AHRQ...) grants policy requires cost transfers to be made promptly after the error occurs but no later than 90 days following occurrence unless a longer period is approved in advance by the GMO.

Completion Date: June 30, 2024

University Contact and Responsible Party: Joseph M. Gindhart, (314) 935-7089



Washington University Summary of Status of Prior Audit Findings Year Ended June 30, 2023

Part IV - Federal Award Findings

Finding 2022-001 Indirect Cost Charges:

During fiscal year 2022, management identified several instances where indirect costs on subawards were not appropriately charged to the sponsor. The error totaled \$3,497,981, of which \$3,475,522 is related to the Research and Development Cluster and the remaining \$22,458 is related to other federal programs.

Status and Action Taken:

The errors noted in the finding have been corrected. Management updated the Basis Limits on the applicable awards and then the correcting entries were processed so that indirect costs on subawards were properly stated and charged to the sponsor. Management continues to monitor the indirect costs on subawards monthly via a customized report which identifies that Basis Limits (e.g., \$25,000 per subaward) are entered and deemed appropriate. Additionally, in September 2022, management added a custom validation in Workday that requires the Basis Limit field to be completed when an out-going subaward is included on a grant.